CURRICULUM VITAE Tarek I. Hassanein, M.D. Business Address: UCSD Liver Center 200 West Arbor Drive, MC8707 San Diego, CA 92103-8707 Phone: (619) 543-7617 Fax: (619) 543-6045 Pager: (619) 290-8330 Email: thassanein@ucsd.edu Date of Birth: 07/13/57 EDUCATION: 1975-1976 Alexandria University, Alexandria, Egypt, Pre-Medicine 1976-1982 Alexandria University, Alexandria, Egypt, M.B.,Ch.B with honors 1984-1987 Alexandria University, Alexandria, Egypt, Master of Science/Internal Medicine 1989- ECFMG 1989- FLEX (PA) 1992-2012 American Board of Internal Medicine, Diplomat 1993-2013 American Board of Gastroenterology, Diplomat 2006-2016 American Board of Internal Medicine, Transplant Hepatology, Diplomat POST- GRADUATE TRAINING: 1992-1994 University of Pittsburgh, Pittsburgh, PA, Fellow GI/Hepatology 1990-1992 Wayne State University, Detroit, MI, Resident, Internal Medicine, PGY II-III 1988-1990 University of Pittsburgh, Pittsburgh, PA, Research Fellow, GI/Hepatology 1984-1987 Alexandria University, Alexandria, Egypt Resident, Internal Medicine, PGY I-III 1983-1984 Military Service, Cairo, Egypt, Internship, Neonatology and Pediatrics 1982-1983 Alexandria University, Alexandria, Egypt, Internship CURRENT POSITION: 2005- Professor of Clinical Medicine & Surgery School of Medicine University of California San Diego, San Diego, CA 1997- Medical Director, UCSD Liver Transplantation 2008- Director Liver Clinical Trials Center UCSD Medical Center, San Diego, CA 2004- Chief of Specialized Liver Cancer Unit Moore’s Cancer Center, UCSD, San Diego, CA CLINICAL APPOINTMENTS: 2008- Medical Director, UCSD Liver Transplantation Program Director, Liver Clinical Trials Center University of California San Diego Medical Center, San Diego, CA 2004- Chief of Specialized Liver Cancer Unit Moore’s Cancer Center, UCSD, San Diego, CA 1997-2008 Chief of Clinical Hepatology Director, UCSD Liver Center Medical Director, UCSD Liver Transplantation Program University of California San Diego Medical Center, San Diego, CA 1995 –1997 Chief of Hepatology and Transplant Gastroenterology Loma Linda University Medical Center, Loma Linda, CA 1994- 1995 Assistant Chief of Transplant Medicine Oklahoma Transplantation Institute Baptist Medical Center of Oklahoma, Oklahoma City, OK ACADEMIC APPOINTMENTS: 2005- Professor of Clinical Medicine and Surgery School of Medicine University of California San Diego, San Diego, CA 1997-2005 Associate Professor of Clinical Medicine and Surgery School of Medicine University of California San Diego, San Diego, CA 1995-1997 Associate Professor of Medicine School of Medicine Loma Linda University, Loma Linda, CA 1994.1995 Visiting Research Associate Pittsburgh Transplantation Institute University of Pittsburgh, Pittsburgh, PA 1987 –1988 Assistant Lecturer School Of Medicine Alexandria University, Alexandria, Egypt AWARDS AND HONORS: 2000 Life member of the National Registry of Who’s Who in the 2000 edition. 1999 “My Boss is a Patriot” Award, United States Naval Reserves 1998 Fellow of American College of Gastroenterology 1997 Fellow, American College of Physicians 1994 ACG/Astra Merck Group Senior Fellow Award 1990 4th Annual Glaxo Fellow Travel Award 1987.1988 Peace-Fellowship Award, US Agency of International Development 1979.1981 Academic Achievement Award 1975-1976 Academic Achievement Award CERTIFICATION AND LICENSURE: Physician License, State of California, #A54452 Physician License, State of Ohio, #35-06-4707 Physician License, State of Michigan, #4301056960 Physician License, State of Pennsylvania, #MD-050954-L Physician License, State of Nevada, #9465 Physician License, Egypt Physician Assistant Supervisor State of California, #SA30942 American Board of Gastroenterology, Diplomat #146759, 1993-2013 American Board of Internal Medicine, Diplomat #146759, 1992-2012 American Board of Internal Medicine, Diplomat, Transplant Hepatology, 2006-2016 ECFMG #415-413-4, 1989 FLEX (PA) #570713015, 1989 MEMBERSHIPS: • American Medical Association • American College of Physicians • American College of Gastroenterology • American Gastroenterological Association • American Association of the Study of Liver Disease • American Society of Transplant Physicians • National Arab American Medical Association • International Liver Transplantation Society • International Gastro-Surgical Club • Gastroenterology Research Group • San Diego Gastroenterology Society • American Liver Foundation San Diego Chapter EDITORIAL BOARD: • Editorial Board, Liver Transplantation • Editorial Board, Hepatology and Gastroenterology • Regional Editor, Hepato-Gastroenterology • Editorial Board, Digestive Diseases & Sciences • Arab Journal of Gastroenterology, International Advisory Board REVIEWER (Past): • Mayo Clinic Proceedings • Journal of Medical Virology • Medical Principles and Practice • Cancer Investigation • Oncology ADVISORY BOARDS/DEVELOPMENT MEETINGS: 1. Faculty 2000 HCV Advisory Board, Roche Laboratories, September 5, 1997. 2. Roferon-A Hepatitis C Advisory Board, Roche Laboratories, January 21, 1998. 3. 1998 Ribavirin Investigators Meeting, Schering, January 29, 1998. 4. Management of Interferon Treatment Failures in Chronic Hepatitis C Roundtable Meeting, Postgraduate Institute for Medicine, March 2, 1998. 5. VPA-985 Investigator Meeting, Wyeth-Ayerst, April 6, 1998. 6. Clinician's Companion II Development Meeting on Hepatitis C, Projects in Knowledge, June 18, 1998. 7. Roundtable Workshop, Management of Interferon Treatment Failures in Chronic Hepatitis C, Dallas TX, 1998. 8. 1999 Rebetron Investigators Meeting, Schering, February 4, 1999. 9. Pegasys Advisory Board, Roche Laboratories, March 19, 1999. 10. Clinician's Companion III Development Meeting on Hepatitis C, June 19, 1999. 11. California Hepatitis C Coalition, 2000 12. Task Force to Develop Strategic Plan for California for Hepatitis C, 2000. 13. SHINE, February, 2000. 14. 2nd Annual Pegasys Global Investigators Event, London, Roche Laboratories, May 3-6, 2001. 15. GI/Hepatology Advisory Board, Beverly Hills CA, November 20, 2001. 16. Pegasys National Advisory Board, Roche Laboratories, March 1-3, 2002. 17. Pegasys Advisory Board, Roche Laboratories, April 6, 2002. 18. Ortho Biotech HCV Regional Ad Board, Symbiotix, August 9, 2002. 19. Consultant, Schering, September 1, 2002-August 31, 2003. 20. GI/Hepatology Regional Advisory Board, Roche Laboratories, March 7-9, 2003. 21. Hepatitis C Advisory Board Meeting, Amgen, Santa Monica CA, November 21-22,2003. 22. Outcomes Research Advisory Board, Roche Laboratories, November 23-24, 2003. 23. Steering Committee, Clinical Research Network in Nonalcoholic Steatohepatitis (NASH/CRN), January 29-30, 2004. 24. AGHC-002 Investigators Meeting, Intermune, March 12-14, 2004. 25. HCV Joint MD/NP/PA Regional Advisory Board, April 23, 2004. 26. Amgen Hepatitis C Advisory Board, Marina Del Rey CA, May 1, 2004. 27. Steering Committee, Nonalcoholic Steatohepatitis Clinical Research Network (NASH CRN), Intermune, June 2004. 28. Hepatology National Advisory Board, Intermune, June 4-6, 2004. 29. Schering Corporation Advisory Board, Schering, July 15-16, 2004. 30. PEGASYS National Advisory Board, Roche Laboratories, August, 2004. 31. Roche Laboratories Advisory Board, September 2004. 32. Intermune Steering Committee, December 2004. 33. AMA CME Hepatitis C Advisory Board, 2005. 34. InterMune Hepatology Regional Advisory Board, April, 2005. 35. Prospectives in Hepatitis C Outcomes: An Educational Network for Improving Options in Treatment Failures (PHOENIX) Advisory Board. 36. Member, Scientific Interest Group, “NeuroAIDS Therapeutics & Comorbidities: Clinical & Laboratory Markers” for the Neuromedical Core of the HIV Neurobehavioral Research Center (HNRC), UCSD Medical School. 37. PEGASYS Speakers Bureau Training, May, 2005. 38. Viramidine Advisory Board, May 2006. 39. Schering Fatigue Advisory Board, June 2006. 40. Roche Counter-IDEAL Advisory Board, August 2006. 41. Valeant Pharmaceuticals Infergen Advisory Board, September 2006. 42. Gilead Sciences HBV National Advisory Board, September 2006. 43. Hepsera Regional Consulting Meeting, Dana Point CA, September 2006. 44. NIDDK Acute Liver Failure Meeting, Bethesda MD, December 2006. 45. 2007 CME Programming Meeting, Paradise Valley AZ, March 2007. 46. Conquering Contemporary Challenges: New Hope with Targeted Therapy for Hepatocellular Carcinoma, CME Innovations ENACH, New York NY, July 2007. 47. “New Management Strategies for HCV Nonresponders and Relapsers”, Author, Online Interactive Case Programs, Clinical Care Options, September 2007. 48. Chronic Liver Disease Foundation HCV/HBV/HE Content Development Meeting, Dallas TX, February 2008. BOOKS AND MEDIA: 1. Hassanein T, Van Thiel DH, Gurakar A. Gut Permeability. In: Update in Intensive Care and Emergency Medicine, Springer-Verlag, Heidelberg (Germany), 1995;128-144 2. Hassanein T, Van Thiel DH. Biochemical abnormalities in liver disease. Bailliere Clinical Gastroenterology 1995;9:679-688. 3. Fagiuoli S, Gurakar A, Hassanein T, et a.. Liver resection and transplantation. In: Consultations in Gastroenterology, Snape W(ed.), W.B. Saunders, New York, 1996;828-842. 4. Advisor “Hepatitis C: A Personal Guide to Good Health”, Royal, B, 1997. 5. Interviewed “Hepatitis What You Need to Know” 1997. 6. “Hepatitis C”, News and Views for Primary Care. Taping, 1997. 7. Dateline Interview. April 2001. 8. "Hepatitis C", June 2001. 9. “Safety Alert! Monitor all Liver Disease Patients for Depression, Anxiety”, Gastroenterology & Endoscopy News, January 2002. 10. San Diego Union Tribune, August 2004. 11. “Blood Purification Systems”, Trauma and Critical Care (in Press). 12. “Tattoos Increase Risk of Contracting Blood-borne Viruses”, North County Times, November 2005. 13. Hepatitis C Radio Tour in 16 cities, September 2006. 14. “TV Anchor Going Public with Hepatitis C Dangers”, San Diego Union Tribune, October 2006. 15. FACE B Speaker Webcast, October 2006. 16. “New Illness Couldn’t Beat Resilient Rolf”, San Diego Union Tribune, November 2006. 17. Health Matters television interview with Channel 8, San Diego CA, January 2007. 18. “Management of HCV Genotype 2/3 Patients”, HCV CME TV, July 2007. 19. You-tube interview with Stan Miller, January 2008. 20. Hepatitis Report, Co-editor, 2007. 21. Hepatitis Report, Co-editor, 2008. 22. WebMD (December, 2008). THESIS ADVISOR: 2004 Mahmoud Abdelsattar Abdel Hamid Mahgoub El Tahawy, Doctor Thesis “Beta Blockers versus Band Ligation or Sclerotherapy in Management of Variceal Bleeding”, Liver Institute of Egypt, Minofaya Egypt. 2003 Jennifer Koh, Master of Thesis, Biology Committee “Micropatterned Co-Cultures of Human Hepatocytes and Stromal Cells: An In Vitro Model of Liver Tissue for Cell- Based Assays”, University of California San Diego, San Diego CA. 2003 Gared Allen PhD. Thesis 1999 Mohamed Salah PhD Thesis 2008 Mahamed Amer PhD Thesis 2008 Fatma Barakat, Master Thesis 2007 Renee Pozza, PhD Thesis COMMITTEE AND ADMINISTRATIVE SERVICES: 2005 UCSD Cancer Committee 2005-2006 Phoenix Steering Committee 2004 UCSD Recruitment Committee 2003 Chief of GI Recruitment Committee, UCSD 2003-2008 Liver Transplant Steering Committee, UCSD, San Diego 2003 Center of Excellence, Gastrointestinal Cancer, UCSD Cancer Center 2003 NASH CRN Steering Committee 2002 LifeSharing Medical Advisory Board 2002 Medical Advisory Board, UNOS, Regional Review Committee 2000-2007 Specialized Cancer Unit, UCSD Cancer Center 2000-2006 International Relations Committee, American College of Gastroenterology 2000-2003 International Liaison Committee, American Gastroenterological Association 2000 Africa-Middle East Regional Advisory Group, American Gastroenterological Association 2000 Liver and Intra-Abdominal Committee, American Society of Transplantation 2000-2001 Education Committee, American Association for the Study of Liver Diseases 2000-2001 State of California Hepatitis C Working Group 2000-2003 San Diego Hepatitis Community Consortium 2000 San Diego County Education Task Force 1999-2000 Translational Oncology, UCSD Cancer Center 1997-2008 Clinical Committee, Division of Gastroenterology, UCSD 1997-2008 Liver Patient Selection Committee, UCSD Liver Center 1997 Strategic Planning Committee, UCSD Liver Center 1997-2008 Medical Advisory Board, Lifesharing, Community Organ Donation 1997-2008 Research Committee, Division of Gastroenterology, UCSD 1997-2008 Medical Advisory Board, ALF San Diego 1999-2008 Board of Directors, ALF San Diego 1997-2000 Committee on Extended Studies and Public Services, Academic Senate, UCSD 1999-2000 Hepatitis C Planning Group, VA Medical Center San Diego 1999-2000 Preceptor, Graduate Nursing Education Program, UCSD 1998 Nutrition Committee, UCSD Medical Center 1998 Hepatitis Task Force, Senator Polanco, State of California 1997-1999 Medical Advisory Board, Kern Hepatitis Association 1997-1999 Cancer Committee, UCSD Medical Center 1996-1999 Board of Directors, Cassie’s Friends, A Gift of Life 1996-1999 Chair, Medical Advisory Board, ALF, Inland Empire Chapter TEACHING ACTIVITIES: 1. “Chronic Acute Hepatitis,” Medicine 401 Clerkship, Veterans Administration Medical Center, La Jolla, CA, July 1997-2008. 2. “ESLD,” Surgery 401 Clerkship, V.A. Medical Center, La Jolla, CA, August 1997 3. “Acute Chronic Hepatitis,” Medicine 401 Clerkship, V.A. Medical Center, La Jolla, CA, November 1997. 4. “Acute Chronic Hepatitis,” Medicine 401 Clerkship, V.A. Medical Center, La Jolla, CA, Jan. 1998. 5. "Hepatitis C", GIM/G Morning Conference, VAMC, January 1998. 6. “ESLD,” Surgery 401 Clerkship, Veterans Administration Medical Center, La Jolla, CA, Feb. 1998. 7. Medical Management Conference, UCSD Department of Medicine, February 1998. 8. Fellow and Resident Teaching on Hepatology/Transplant Service, UCSD, March 1998. 9. "Interpretation of Liver Injury Tests" GIM/G Morning Conference, VAMC, March 1998. 10. "Biliary Disease", SOM 208, April 1998. 11. Medicine Attending, UCSD, April 1998. 12. “Post-op Liver Transplant Management” SICU nurses, UCSD, May 1998. 13. “Chronic Hepatitis” Medicine 401 Clerkship, UCSD, May 1998. 14. “ESLD” Surgery 401 Clerkship, UCSD, June 1998. 15. “HIV/HCV Co-Infection” UCSD AIDS Clinical Rounds, June 1998. 16. "Hepatitis A through E, Part 1: The Virus, The Disease" UCSD Liver Center, Inpatient services, July 1998. 17. "HIV/HCV Co-Infection" UC Irvine Grand Rounds, July 1998. 18. "Chronic Hepatitis" Medicine 401 Clerkship, UCSD, July 1998. 19. "Ascites" Internal Medicine Noon Conference, UCSD, August 1998. 20. "ESLD" Surgery 401 Clerkship, UCSD, September 1998 21. "Chronic Hepatitis", Medicine 401 Clerkship, UCSD, October 1998. 22. "Hepatitis Update", Internal Medicine Group, UCSD, October 1998. 23. "Liver Failure in the SICU", SICU, UCSD, October 1998. 24. "End Stage Liver Disease" Surgery 401 Clerkship, UCSD, October 1998. 25. "Hepatitis C Update", Grand Round, UCSD Nurse Practitioner Group, October 1998. 26. "Cirrhosis and Portal Hypertension" Surgery Resident Conference, UCSD, December 1998. 27. "Alcoholic Liver Disease" Internal Medicine Conference, VA Medical Center, January 1999. 28. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, February 1999. 29. "ESLD" Surgery 401 Clerkship, UCSD, March 1999. 30. "Auto immune hepatitis" UCSD Medical Management Conference, March 1999. 31. "Induction vs. combination therapy" GI Research Seminar, April 1999. 32. "Biliary Disease" SOM 208, April 1999. 33. "ESLD" Surgery 401 Clerkship, UCSD, May 1999. 34. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, May 1999. 35. OSCE Course, UCSD, May 1999. 36. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, July 1999. 37. “Hepatitis” Medicine Grand Rounds, VAMC, August 1999. 38. “Split Liver Transplantation” GI Grand Rounds, UCSD, September 1999. 39. “Ascites”, Medicine Noon Conference, UCSD, October 1999. 40. “Hepatitis C and Liver Transplant Update”, Medical Grand Rounds, VAMC, October 1999 41. Medical Management Conference, Internal Medicine, UCSD, November 1999. 42. “Combination Therapy”, Hepatitis C Support Group, UCSD, November 1999. 43. Student Teaching, MED 496, UCSD SOM, Fall 1999. 44. Student Teaching, MED 299, UCSD SOM, Winter 1999. 45. “FHF”, GI Grand Rounds, UCSD, January 2000. 46. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, January 2000. 47. Introduction to Clinical Medicine 201B, ICM Course, January 2000. 48. “Mechanisms of Hepatic Fibrogenesis” Basic Science Seminar, UCSD, February 2000. 49. “Hepatorenal Syndrome”, Post-graduate Course in Surgery, UCSD, Department of Surgery, February 2000. 50. Student Teaching, MED 467, UCSD SOM, March 2000. 51. “Alcoholic Liver Disease” Basic Science Seminar, UCSD, April 2000. 52. “Fulminant Hepatic Failure” SICU, UCSD Medical Center, April 2000. 53. “Acute Chronic Hepatitis” Medicine 401 Clerkship, UCSD, April 2000 54. “Hepatic Cirrhosis” SOM 208 Human Disease, UCSD, April 2000. 55. Objective Structured Clinical Exam, UCSD, April 2000. 56. Student Teaching, ISP, UCSD SOM, May 2000. 57. “DDW Update” Grand Rounds, Div of GI, June 2000. 58. “A B C’s of Hepatitis: Emphasis on C”, Fallbrook Hospital Grand Rounds, June 2000. 59. “Acute Chronic Hepatitis”, Medicine 401 Clerkship, UCSD, July 2000. 60. “Update on Hepatitis C Treatment”, UCSD Liver Center Hep C Support Group, August 2000. 61. “Acute Liver Failure”, Basic Science Seminar, GI Division, August 2000. 62. “Fulminant Hepatic Failure”, Grand Rounds, Medical College of Georgia, GI Division, September 2000. 63. “New Therapies for Hepatitis C”, Grand Rounds, University of South Carolina, GI Division, September 2000. 64. “Ascites”, Medical Residents Lecture, VAMC, September 2000. 65. “Viral Hepatitis” Medicine 401 Clerkship, UCSD, October 2000. 66. “Hepatitis C”, Grand Rounds, Northridge Medical Center, Northridge CA, November 2000. 67. "Viral Hepatitis" Medicine 401 Clerkship, UCSD, January 2001. 68. “Hepatitis in the Dialysis Patient”, UCSD Nephrology Post-graduate Course, February 2001. 69. “Hepatitis and Primary Liver Tumors”, UCSD Post-graduate Assembly in Surgery, February 2001. 70. Objective Structured Clinical Exam, UCSD, April 2001. 71. “Cirrhosis” SOM 208 Human Disease, UCSD, April 2001. 72. "Hep C," I.M. Grand Rounds, VAMC Feb 2001. 73. "Hep B," I.M. Grand Rounds, VAMC March 2001. 74. "MARS," G.I. Research, UCSD March 2001. 75. "Viral Hepatitis and HCC," Trans Onc., UCSD Cancer Center April 2001. 76. "Viral Hepatitis", Medicine 401 Clerkship, May 2001. 77. "Viral Hepatitis", Medicine 401 Clerkship, July 2001. 78. "Acute Liver Failure", Basic Science Seminar, VAMC, August 2001. 79. “Hepatitis C”, Medicine Rounds, Scripps Memorial Hospital, Chula Vista CA, August 2001. 80. "Update on Research Practices" Liver Conference, UCSD Liver Center, September 2001 81. "Hepatitis C", Family Medicine Grand Rounds, October 2001. 82. "Viral Hepatitis", Medicine 401 Clerkship, October 2001. 83. "Management Techniques of Hepatitis C", Internal Medicine Grand Rounds, Alvarado Medical Center, November 2001. 84. "Drug Induced Liver Disease", Basic Science Seminar, GI, UCSD, January 2002. 85. "HBV" VAMC General Internal Medicine Grand Rounds, January 2002. 86. "Viral Hepatitis", Medicine 401 Clerkship, February 2002. 87. "Bacterial and Parasitic Infection of the Liver", Basic Science Seminar, GI, UCSD, March 2002. 83. Report on UCSD Liver Center Activities" GI Retreat, UCSD, March 2002. 88. “Cirrhosis” SOM 208 Human Disease, UCSD, April 2002. 89. "Transition of Lab Inventions to the Clinical Setting" Biomedical Group, UCSD, April 2002. 90. "Live Your Life" N.P, R.N., P.A. Speaker Training April 2002. 91. "M.A.R.S Update” Grand Rounds, Div of GI, May 2002 92. "Viral Hepatitis", Medicine 401 Clerkship, June 2002. 93. American Academy of Family Practitioners, November, 2002 94. “Viral Hepatitis”, Medicine 401 Clerkship, March 2003. 95. "Viral Hepatitis", Medicine 401 Clerkship, November 2003 96. “Drug Induced Liver Disease”, Basic Science Seminar, November 2003 97. “Mechanisms of Hepatic Fibrogenesis”, Basic Science Seminar, November 2003 98. "Viral Hepatitis", Medicine 401 Clerkship, February 2004. 99. "Viral Hepatitis", Medicine 401 Clerkship, June 2004. 100. Gilead Sciences Hepatitis B Speakers’ Bureau, June 2004 101. "Viral Hepatitis", Medicine 401 Clerkship, July 2004. 102. “Human Disease”, UCSD, School of Medicine, July 2004 103. “Emerging Advances in HCV Management”: A PEGASYS Educational Program, Tucson AZ, November 2004. 104. “Hepatitis C Clinical Practice: Present & Future”, San Diego CA, November 2004. 105. “Hemostatis Grand Rounds: Excessive Bleeding in Medical and Surgical Cases, San Diego CA, January 2005. 106. “Organ Physiology” UCSD School of Medicine, March 2005 107. Grand Rounds, Palomar Medical Center, Escondido CA, May 2005. 108. “Acute & Chronic Hepatitis”, GI Core Lecture Series, June 2005. 109. Acute and Chronic Hepatitis” Medicine 401 Clerkship, UCSD, July 2005. 110. “Extra Corporeal Albumin Dialysis (ECAD): A New Approach to Liver Disease”, UCSD Department of Medicine Grand Rounds, San Diego CA, August 2005. 111. “Extra Corporeal Albumin Dialysis (ECAD): A New Approach to Liver Disease”, UCLA Department of Medicine Grand Rounds, Los Angeles CA, August 2005. 112. “Hepatitis C”, Grand Rounds, Torrance Memorial Medical Center, Torrance CA, August 2006. INVITED LECTURES: 1. “Nutritional therapy for alcoholic hepatitis,” Nutrition Support Service, University of Pittsburgh Medical Center, March 1993. 2. “Emerging treatment for viral hepatitis,” GI Medical-Surgical Conference, University Health Science Center, Portland OR, April 1994. 3. “Gut Permeability,” First International Symposium on Applied Physiology of the Peripheral Circulation, Barcelona, Spain, September 1994. 4. 4th International Congress of Therapeutic Drug monitoring and Clinical Toxicology, Vienna, Austria, September 1995. 5. International Workshop on “Epidemiology, Diagnosis and Management of Hepatitis C Infection,” Medical Research Institute, University of Alexandria, Egypt, October 1995. 6. “Conventional Medical and Surgical Management of Fulminant Hepatic Failure,” International Conference for Apheresis, Kyoto, Japan, April 1996. 7. “Update on Small Bowel Transplantation,” University of St. Louis, St. Louis MO, February 1996. 8. “Update on Hepatitis C,” The Liver Institute, Menofyia, Egypt, March 1996. 9. "Organ Transplants: Complications and Management" US Family Care Medical Center Education Program, February 1997. 10. "Update on Hepatitis", 20th Annual San Diego Postgraduate Assemble in Surgery, February 1997. 11. “Risk and Management of Hepatitis” Dialysis and Transplant Management, April 1997. 12. “New Treatment in Hepatitis” Dialysis and Transplant Management, April 1997. 13. “Liver Transplant Who and When,” Basic Science Seminar, UCSD, La Jolla CA, July 1997. 14. “New Therapies for HCV,” Veterans Administration Medical Center, La Jolla CA, August 1997. 15. “Management of Viral Hepatitis,” Alvarado Medical Center, San Diego CA, September 1997. 16. “Update on Liver Transplantation” Palomar Hospital, Escondido CA, October 1997. 17. “What’s New in Liver Disease,” Scripps Hospital, La Jolla CA, October 1997. 18. “Hepatitis C,” GI and Hep Update, La Jolla CA, November 1997. 19. “Hepatitis B and C,” SD Family Health, San Diego CA, January 1998. 20. “Hepatitis C, the Silent Killer,” UCSD Medical Center, San Diego CA, January 1998. 21. “Hepatitis C,” Veterans Administration Medical Center, La Jolla CA, January 1998. 22. "Hepatitis: Its diagnosis and current treatments", 23rd Annual Postgraduate course Topics and Advances in Internal Medicine, February 1998. 23. “Hepatitis Therapy,” Canji, La Jolla CA, February 1998. 24. “Hepatitis Dx/Tx,” La Jolla CA, February 1998. 25. “Diagnosis of Hepatitis,” Scripps Hospital, Chula Vista CA, February 1998. 26. “Case Presentation,” UCSD Medical Center, San Diego CA, February 1998. 27. “Fulminant Hepatic Failure,” Veterans Administration Medical Center, La Jolla CA, March 1998. 28. “GI Bleeding Banding vs Sclerotherapy,” SCSGNA Long Beach CA, March 1998. 29. “Interpretation of Liver Injury Tests,” Veterans Administration Medical Center, La Jolla CA, March 1998. 30. “Hepatitis C, the Silent Killer,” ALF San Diego North County, Escondido CA, March 1998. 31. “Hepatitis B & C,” Center for Health, Poway CA, March, 1998. 32. “HCV/HIV,” Navy Hospital, April 1998. 33. “Interpretation of Liver Enzyme Values,” CC of Nurse Practitioners, Redlands CA, April 1998. 34. “Hepatitis B and C Treatment,” Yuma Medical Center, Yuma AZ, April 1998. 35. “Biliary Disease,” UCSD, La Jolla CA, April 1998. 36. “Hepatitis and Renal Failure” Dialysis and Transplant Management, April 1998. 37. “Viral Hepatitis Update” Rational Therapeutics Annual Seminar, Anaheim CA, June 1998. 38. “Lamivudine in Treatment of Hepatitis B in the Transplant Patient” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998. 39. “FK-506 Immunosuppression and its Management” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998. 40. “Lamivudine in Treatment of Hepatitis B” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998. 41. “New Protocol for DT Artificial Liver” Egyptian Society of Tropical Medicine, Infectious and Parasitic Diseases Annual Congress, June 1998. 42. “Liver Transplant Update” Misr International Hospital, Egypt, June 1998. 43. “Hepatitis ABC 1998” Family Medicine Update 1998, San Diego CA, June 1998. 44. “Hepatitis C Research and Treatment: What you should know about your own treatment” Kern Hepatitis Association, Bakersfield CA, June 1998. 45. “Hepatitis C: What's New and in the News in 98” Kern Hepatitis Association, Bakersfield CA, June 1998. 46. "Clinical Interventions for HCV" HCV Global Foundation 2nd International HCV Conference, Oakland CA, August 1998. 47. "Post-op Liver Transplant Living" ALF, Inland Empire Chapter, September 1998. 48. "HIV/HCV Co-Infection", Inland Aids Project, November 1998. 49. "Viral Hepatitis Update" 1998 UCSD Gastroenterology Hepatology Update, November 1998. 50. "Hepatitis Overview", Kern Hepatitis Association, Bakersfield CA, November 1998. 51. "Hepatitis B and C an Overview", Hepatitis Community Forum, ALF Inland Empire, November 1998. 52. "Induction vs. Combination Therapy" Washington University, St. Louis MO, December 1998. 53. "Liver Failure", 22nd Annual San Diego Postgraduate Assembly in Surgery, UCSD, February 1999. 54. "Hepatitis C", 24th Annual Topics and Advances in Internal Medicine, UCSD, February 1999. 55. "Hepatitis C", UCSD Liver Center Support Group, March 1999. 56. "Update on Hepatitis C", UCSD Transplant Support Group, April 1999. 57. "Hepatitis Debate", Pacific Aids Education and Training Center, April 1999. 58. "Hepatitis", ESRD Management Conference, April 1999. 59. “Current Status of Liver Transplantation”, Orange County Hepatitis C Support Group, May 1999. 60. “Hepatitis A, B, and C for Healthcare Professionals”, Naval Reserve, Naval Medical Center San Diego, September 1999. 61. “New Approaches in the Treatment of HCV”, Hepatitis C Y2K, UCSD, September 1999. 62. “Special Considerations in Patient Management”, Recent Advances in the Treatment of Hepatitis C, Chicago IL October 1999. 63. “Current Hepatitis C Issues”, ALF, San Diego CA, October 1999. 64. “Viral Hepatitis”, 5th Annual Management of Common Gastrointestinal and Liver Diseases, UCSD, November 1999. 65. “ESLD: Pathophysiology and Management Strategies”, Nephrology for the Consultant, San Diego CA, February 2000. 66. “Management of Liver Failure: New Directions” Topics and Advances in Internal Medicine, San Diego CA, February 2000. 67. “Management of Biliary Obstruction” Clinical Symposium, Topics and Advances in Internal Medicine, San Diego CA, February 2000. 68. “What is Hepatitis C?”, Azusa Pacific University, Azusa CA, February 2000. 69. “Hepatic Failure”, 5th International Conference on CRRT, San Diego CA, March 2000. 70. “Hepatitis C Standard Therapies”, Hepatology for the Primary Care Provider, April 2000. 71. “HCV Therapies in the Year 2000”, Alexandria Armed Forces Hospital, April 2000. 72. “An Update on Liver Transplantation”, Alexandria Armed Forces Hospital, April 2000. 73. “Clinical issues in Hepatitis C’, Pinnacle Communications, Beverly Hills CA, April 2000. 74. “Hepatitis C”, Oasis Independent Physician Association, Palm Springs CA, May 2000. 75. “Natural History of Hepatitis C” Innovations in the Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000. 76. “Current Strategies for the Diagnosis and Treatment of Hepatitis C”, Innovations in the Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000. 77. “Side Effects Management”, Innovations in the Management of Hepatitis C, Tim Rice and Associates, Beverly Hills CA, May 2000. 78. “HIV and HCV” Hepatitis on the Front Line, UCI, Irvine CA, May 2000. 79. “Role of the PCC in the Diagnosis and Treatment of Hepatitis C”, Hepatitis Education Initiative, June 2000. 80. “Diagnosis and Standard Therapy of Hepatitis C”, Hepatitis C Symposium, UCSD Liver Center, June 2000. 81. “Liver Update”, Post DDW Conference, San Diego, CA, July 2000. 82. “Treating Hepatitis C”, Solutions for a Critical Need, Newport Beach CA, July 2000. 83. “Fulminant Liver Support and New Management”, Critical Care Summer Session, July 2000. 84. “Natural History of Hepatitis C and Current Strategies for the Management of Hepatitis”, Hepatitis Treatment Advocacy, August 2000. 85. “Hepatitis A, B, C”, Hemophilia Council of California, San Diego CA, August 2000. 86. “HIV/HCV Co-Infection”, Department of Health Services, Office of AIDS and Early Intervention Program, State of California, August 2000. 87. “Cholestasis”, International Symposium on Albumin Dialysis in Liver Disease, University of Rostock, Germany, September 2000. 88. “Clinical Issues in Hepatitis C”, Pinnacle Communications, Marina Del Rey CA, September 2000. 89. “Update on Hepatitis C”, American Liver Foundation Patient Support Group, September 2000. 90. “Hepatitis C”, Medical College of Georgia, GI Division, September 2000. 91. “Treating Hepatitis C” Emory University, September 2000. 92. “Overview of Hepatitis C”, Boron, Las Vegas, October 2000. 93. “Innovations in the Management of Hepatitis C”, Symbiotix, Santa Monica CA, October 2000. 94. “Hepatitis Treatment”, American Liver Foundation Public Forum, San Diego CA, October 2000. 95. “Diagnosis and Management of Hepatitis C”, Current Trends in Women’s Health, San Diego CA, November 2000. 96. “Treatment Strategies in Managing HCV”, BLP, Eugene OR, November 2000. 97. “Treatment Strategies in Managing HCV”, BLP, Holtville CA, November 2000. 98. “Special Considerations in Patient Management” Promeda, Beverly Hills CA, November 2000. 99. “AASLD Medical Update”, ALT Staff Leadership Meeting, San Diego CA, December 2000. 100. “Hepatitis: Diagnosis, Treatment and Prevention”, RCH Foundation, December 2000. 101. “Hepatitis B/C”, UCSD Student Health Services, January 2001. 102. “Treatment Strategies in Managing Chronic HCV: Emerging Data on Pegylated Interferons”, Rush-Presbyterian-St. Luke's Medical Center CME, San Diego CA, February 2001. 103. “Management of Decompensated Liver Disease: Detoxification Systems” Sixth International Conference on CRRT, San Diego CA, March 2001. 104. “The Role of the General Internist in Managing Hepatitis C: New Concepts” Conference: Topics and Advances in Internal Medicine, UCSD, San Diego CA, March 2001. 105. “HCV Treatment Update”, ALF Support Group, March 2001. 106. “Post-Operative Care of Liver Transplant Patients”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001. 107. “HBV Update”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001. 108. “New Modalities in the Management of Liver Failure”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001. 109. “Novel Therapies of Hepatitis B Infection”, The African Middle East Association of Gastroenterology, (AMAGE Congress), Cairo, Egypt, April 2001. 110. “Hep C”, Alexandria University Department of Medicine, April 2001. 111. “FHF”, Alexandria University Department. of Medicine, April 2001. 112. “Viral Hepatitis: Prevention and Clinical Care”, San Diego Hepatitis Community Consortium, San Diego CA, April 2001. 113. “Albumin Dialysis”, UCSD Liver Center, San Diego CA, May 2001. 114. “Life Support Systems - The MARS System”, SCTI Research Foundation Yearly Update on ESRD & Kidney Pancreas Transplant Management, May 2001. 115. “Managing Chronic HCV: Emerging Data on Pegylated Interferons”, Rush-Presbyterian-St. Luke's Medical Center, Irving Texas, May 2001. 116. “Achieving Optimum Outcomes: Customizing Treatment for Patients with HCV Infection”, Educational Initiative in Gastroenterology, Newport Beach CA, May 2001. 117. “Hepatic Encephalopathy-Impact of MARS Treatment”, 3rd International Symposium on Albumin Dialysis in Liver Disease, Rostock, Germany, September 2001. 118. “HCV/HIV Co-Infection”, New Horizons in Hepatology, UCSD Liver Center, San Diego, CA, September 2001. 119. “Liver Support Systems in Practice”, New Horizons in Hepatology, UCSD Liver Center, San Diego CA, September 2001. 120. "Day of Remembrance", Lifesharing, November 2001. 121. "HIV/HCV Co-Infection", Comprehensive Care Center, November 2001. 122. “Hepatitis C”, Desert Hospital, Palm Springs CA, November 2001. 123. "HIV and HCV Co-infection", 15th Annual HIV/AIDS on the Front Line Conference, March 2002. 124. "Live Your Life” Management of Hepatitis C, April 2002. 125. “Controversies of the Liver”, USD, San Diego CA, July 2002. 126. “Complications of Liver Disease and Acute Liver Failure”, VA Medical Center, La Jolla CA, August 7, 2002. 127. “HIV/HCV Co-Infection” Ortho Biotech, Los Angeles CA, August 2002. 128. “Albumin Dialysis Liver Disease, International Symposium, Rostock, Germany, September 2002. 129. “Hepatitis & STDs”, San Diego Hepatitis Consortium, San Diego CA, September 2002. 130. “HCV”, Summit Institute of Knowledge, Pasadena CA, September 2002. 131. “Hepatitis A-G”, AAFP Scientific Assembly, La Jolla CA, October, 2002 132. “HIV/HCV CoInfection”, Hoag Hospital, Newport Beach CA, October 2002 133. “Hepatitis C and Organ Transplantation”, Advances in Transplantation, La Jolla CA, October 2002. 134. “HIV/HCV Co-Infection”, American Liver Foundation, San Diego CA, October 2002. 135. “Esophageal Varices”, UCSD, San Diego CA, November 2002. 136. “HIV/HCV Co-Infection”, National Minority Aids Council Regional Conference, San Diego CA, November 2002. 137. “Maximizing Treatment Outcomes for Patients with Hepatitis C”, AdvanceMed, Lubbock TX, February 2003. 138. “HIV and HCV Co-Infection”, Department of Public Health Services Office of Aids and Early Intervention Program, State of California, Anaheim, CA, February 2003. 139. “Hepatitis and Hepato-Cellular Carcinoma”, Assembly in Surgery, UCSD, San Diego, CA, February 2003. 140. “New Therapy in the Management of Chronic Hepatitis C”, Pegasys Education Program, Las Vegas NV, February 2003. 141. “Emerging Advances of HCV Management”, Pegasys Education Program, Tucson AZ, April 2003. 142. “Emerging Advances of HCV Management”, Pegasys Education Program, Amarillo TX, April 2003. 143. "Hepatocellular Carcinoma and Liver Transplantation", Health Professionals Educational Seminar, Hepatitis B Prevention Project, San Diego CA, June 2003. 144. “Emerging Advances of HCV Management”, Pegasys Education Program, Greenwood Village CO, September 2003. 145. “Current Treatment of Hepatitis”, ESRD Kidney/Pancreas Transplant Management Conference, Ontario CA, October 2003. 146. “Management of End Stage Liver Disease”: ESRD Kidney/Pancreas Transplant Management Conference, Ontario CA, October 2003. 147. “Viral Hepatitis: Prevention, Management Future Perspective”, American Liver Foundation STD/Hepatitis Prevention Program, County of San Diego, San Diego Hepatitis Community Consortium, October 2003. 148. “Management of HCV Infection in Patients Who Are Nonresponders to Previous Therapy”, Boston MA, October 2003. 149. “Hepatitis C”, El Centro CA, January 2004 150. “Hepatitis C in the Patient with ESRD”, San Diego CA, January 2004. 151. “Treatment of Hepatitis C”, First Annual Postgraduate Course, Cairo, Egypt, February, 2004. 152. “The Hepatologist’s View”, 27th Annual San Diego Postgraduate Assembly in Surgery, February 2004. 153. “Hepatitis B, When and How to Treat”, Topics and Advances in Internal Medicine Postgraduate Course, San Diego CA, February 2004. 154. “Hepatic Failure”, 9th International Conference On Continuous Renal Replacement therapies, San Diego CA, March 2004 155. “Treatment Options for the HCV Nonresponder”, Intermune, San Diego CA, March 2004. 156. “Treatment Options for the HCV Nonresponder”, Intermune, Las Vegas NV, March 2004. 157. “Medical Aspects of Liver Transplantation,” First Madinah International Symposium on Diseases of the Gastrointestinal Tract, Cairo, Egypt, March 2004 158. “Evaluation and Management of Acute Liver Failure”, Hepatology: State of the Art, Mayo Clinic-Rochester, San Diego CA, April 2004 159. “HCV/HIV Coinfection”, Pegasys Speakers Bureau, Roche Laboratories, Phoenix AZ, April 2004. 160. “Treatment Options for the HCV Nonresponder,” Intermune, San Diego CA, April 2004 161. Treatment Options for the HCV Nonresponder,” Intermune, EL Paso TX April 2004 162. “Treatment Options For The HCV Nonresponder”, Intermune, San Diego CA, May 2004. 163. “What to do for a Patient with Hepatitis B Infection: A Systematic Approach for Diagnosis and Treatment”, Asian Pacific Health Center, San Diego CA, June 2004. 164. “Treatment Options For The HCV Nonresponder”, Intermune, Dallas TX, Houston TX, June 2004 165. “Hepatitis B Prevention”, Hepatitis Educational Seminar, San Diego CA, June 2004. 166. “Treatment Options for the HCV Nonresponder”, Hepatology Regional Advisory Board, Boston MA & New York, NY, June 2004 167. “DIRECT Trial Awareness”, Intermune, San Diego CA, June & July 2004. 168. “HCV & HIV Crossroads: Integrating Treatment Strategies in the Coinfected Patient”, Fresno CA, July 2004. 169. “Treatment Options for the HCV Nonresponder,” Intermune, Ashland OR, August 2004. 170. “Treatment Options for the HCV Nonresponder,” Intermune, Chicago IL August 2004. 171. “Treatment Options for the HCV Nonresponder,” Intermune, Santa Rosa CA, August 2004. 172. “HIV & HCV Crossroads: Integrating Treatment Strategies in the Coinfected Patient”, Austin TX, September 2004. 173. “Hepatic Encephalopathy”, 6th International Symposium on Albumin Dialysis in Liver Disease, Rostock, Germany, September, 2004. 174. “Hepatitis C Update”, SCSGNA Fall Conference, Pala CA, October 2004. 175. “Treatment Options for the HCV Nonresponder”, Intermune, Anaheim CA, October 2004. 176. “Treatment Options for the HCV Nonresponder”, Intermune, Newport Beach CA, October 2004. 177. “Treatment Options for the HCV Nonresponder”, Intermune, Riverside CA, October 2004. 178. “Treatment Insights: Advances in the Management of Chronic Hepatitis B,” San Diego CA, October 2004. 179. “Navigating the Obstacles to Hepatitis C Management: Keeping the Patient on Course,” Houston TX, October 2004. 180. “The 2ndTime Around: Retreatment Strategies for the Patient with HCV Infection,” Education Initiative in Gastroenterology, Boston MA, October 2004. 181. “Hepatitis C”, Infectious Disease Seminar, San Bernardino CA, November 2004. 182. “Treatment Options for the HCV Nonresponder”, Intermune, Pico Rivera CA, November 2004. 183. “MARS, a New Technology for Supporting Liver Failure”, San Diego CA, November 2004. 184. “Treatment Options for the HCV Nonresponder,”, Intermune, Beverly Hills CA, November 2004. 185. Treatment Options for the HCV Nonresponder,”, Intermune, Tucson AZ November 2004. 186. “Hepatitis B The Silent Killer,” Phoenix AZ, November 2004. 187. “DIRECT Trial Awareness,” Intermune, Downey CA, November 2004. 188. “Treatment Options for the HCV Nonresponder,” Intermune, Nichols Hills OK, December 2004. 189. “Treatment Options for the HCV Nonresponder”, Intermune, Hemet CA, January 2005. 190. “Emerging Advances in HCV Management”: A PEGASYS Educational Program, Hershey PA, December 2004 191. “Treatment Options for the Nonresponder,” Intermune, Chapel Hill NC, December 2004. 192. Treatment Options for the Nonresponder,” Intermune, Sacramento CA December 2004. 193. Treatment Options for the Nonresponder,” Intermune, San Diego CA December 2004. 194. “Treatment Options for the HCV Nonresponder”, Infergen, Las Vegas NV, January 2005. 195. “Approaches to Managing & Treating Chronic Hepatitis B,” San Diego CA, February 2005. 196. “Emerging Advances in HCV Management”, Post AASLD, Roche, Hemet CA, February 2005. 197. “DIRECT Trial Awareness” Intermune, San Diego CA, February 2005 198. “DIRECT Trial Awareness” Intermune, Riverside CA, February 2005 199. “MARS: A New Technology for Supporting Liver Failure”, 10th International CRRT Conference, San Diego CA, March 2005 200. “Treatment Strategies for the HCV Nonresponder”, Intermune, Irvine CA, March 2005. 201. “DIRECT Trial Awareness”, Intermune, Oklahoma City OK, March 2005. 202. “DIRECT Trial Awareness”, Intermune, El Paso TX, March 2005. 203. “Liver Disease At the Crossroads of Civilization: East Meets West”, Alexandria, Egypt, March 2005. 204. “Retreatment Strategies for the Patient with the HCV Infection”, Projects in Knowledge, Accreditation Council for Continuing Medical Education (ACCME). 205. “Emerging Advances in HCV/HIV Coinfection: An Evidence Based Approach”, Roche, Tucson AZ, April 2005. 206. “Treatment Strategies for the HCV Nonresponder”, Intermune, San Antonio TX, April 2005. 207. “Treatment Strategies for the HCV Nonresponder”, Intermune, Austin TX, April 2005. 208. “Treatment Strategies for the HCV Nonresponder”, Intermune, Salt Lake City UT, April 2005. 209. “DIRECT Trial Awareness”, Intermune, Tucson AZ, April 2005. 210. “Emerging Advances in HCV/HIV Coinfection”, Roche, Fresno CA, April 2005. 211. “DIRECT Trial Awareness”, Intermune, Augusta GA, April 2005. 212. International Hepatitis B Symposium, Abu Dhabi, UAE, May 2005. 213. “Practical Pathways Towards Improved Management of HCV Treatment Failures”, Chicago IL, May 2005. 214. “Emerging Advances in HCV/HIV Coinfection: An Evidence Based Approach”, Roche, San Diego CA, May 2005. 215. Treatment Strategies for the NCV Nonresponder, Intermune, La Jolla CA, May 2005. 216. “DIRECT” Trial Awareness”, Intermune, Costa Mesa CA, May, 2005. 217. 12th International Symposium on Hepatic Encephalopathy and Nitrogen Metabolism, Dusseldorf, Germany, June 2005. 218. “Treatment Strategies for the HCV Nonresponder”, Intermune, San Diego CA, June 2005. 219. “Treatment Strategies for the HCV Nonresponder”, Intermune, Portland OR, June 2005. 220. “Treatment Strategies for the HCV Nonresponder”, Intermune, Seattle WA, June 2005. 221. “What You Need to Know About Colon Cancer”, Riverside Community Hospital, Riverside CA, July 2005. 222. “A Clinical Plan for the Hepatitis C Nonresponder and Relapse Patient”, National Nurses Advisory Council, Hepatitis Foundation International, Orange CA, July 2005. 223. “Improving Treatment of HCV by Community Health Centers”, National Association of Community Health Centers, Denver CO, July 2005. 224. “Co-Infection: Treatment & New Therapies”, American Liver Foundation, Viral Hepatitis 2005 Community Impact, September 2005. 225. “Evaluating Patients Infected with the Hepatitis B Virus and Selecting Candidates for Antiviral Treatment”, Gastroenterology-Hepatology Impact 2006, Phoenix AZ, January 2006. 226. “Stigma in Chronic Disease”, The 5th California Inter-County Annual Hepatitis C Task Force Conference, Riverside CA, April 2006. 227. “Treatment Strategies for the HCV Nonresponder”, Valeant, Bethesda MD, April 2006. 228. “Treatment Strategies for the HCV Nonresponder”, Valeant, Baltimore MD, April 2006. 229. “HCV in Special Populations”, Roche, Albuquerque NM, April 2006. 230. “Where do we go from here? Emerging Strategies in the Management of HCV Treatment Nonresponders”, 2nd Annual Hepatitis Center Update in Liver Disease, Austin TX, May 2006. 231. “Overview of Hepatitis B Therapies”, Gilead, Paradise Valley AZ, May 2006. 232. “Treatment Strategies for the HCV Nonresponder”, Valeant, Newport Beach CA, May 2006. 233. “MARS”, Annual North American Pediatric Renal Transplant Cooperative, Las Vegas NV, May 2006. 234. “Optimizing Treatment in Viral Hepatitis: Advances in Patient Care”, Roche, Phoenix AZ, June 2006. 235. “HCV”, Roche, Grossmont CA, June 2006. 236. “HCV in Special Populations”, Roche, San Diego CA, June 2006. 237. “Treatment Strategies for the HCV Nonresponder”, Valeant, Chicago IL/ Philadelphia PA/ Worchester MA/ Tulsa OK, June 2006. 238. Home Office Training Program, Valeant, Costa Mesa CA, July 2006. 239. “Optimizing Treatment of Viral Hepatitis: Advances in Patient Care”, Las Vegas NV, August 2006. 240. “HCV Treatment Today: From Evidence to Clinical Practice”, Shanghai China, July 2006. 241. Reach Educational Advances in Chronic HBV”, Gilead, July 2006. 242. “Optimizing Treatment of Viral Hepatitis: Advances in Patient Care”, Roche, July 2006. 243. “Understanding NASH and its Treatment” / “Autoimmune Hepatitis” / “Treatment for Hepatitis B and C”, Central American GI Congress, El Salvador, July 2006. 244. “Chronic Hepatitis B: Baraclude as First-Line Treatment Option in Nucleoside-Naïve Patients”, Bristol-Myers Squibb, Newport Beach CA, August 2006. 245. Pegasys Live Speaker Program, El Centro CA, September 2006. 246. “Current Approaches to HCV Failures of IFN-based Therapies in HCV Infection”, Beth Israel Hospital, New York, September 2006. 247. “Treatment Strategies for the HCV Nonresponder”, Valeant, La Jolla CA, September 2006. 248. “Diagnosing the Patient; Natural History and Progression of Liver Disease”, NACHC HCV Initiative Symposium, San Diego CA, October 2006. 249. “Treatment Strategies for the HCV Nonresponder”, Orange County Gut Club, Fullerton CA, November 2006. 250. “New Concepts in the Treatment of Hepatitis C”, Riverside CA, November 2006. 251. “Current Status and Future Direction in the Management of Viral Hepatitis”, Pfizer, November 2006. 252. “Treatment Strategies for the HCV Nonresponder”, Salt Lake City UT, November 2006. 253. “Clinical Insights of Chronic Liver Disease” Meeting and Teleconference, San Diego CA, December 2006. 254. “Managing Hepatitis C Hot Topics 2006”, Spokane WA, December 2006. 255. “Evaluation Patients Infected with Hepatitis B Virus and Selecting Candidates for Antiviral Treatment”, IMPACT Hepatology-Gastroenterology, Laguna Niguel CA, December 2006. 256. “Simply Speaking HBV: An Expert Educator’s CME Lecture Series”, San Diego CA, January 2007. 257. “ABCs of Hepatitis A, B and C”, 30th Annual San Diego Postgraduate Assembly in Surgery, San Diego CA, February 2007. 258. “Management of Variceal Hemorrhage from Portal Hypertension”, 30th Annual San Diego Postgraduate Assembly in Surgery, San Diego CA, February 2007. 259. “Hepatitis C: The Current Epidemic”, 20th International Conference on Antiviral Research, Palm Springs CA, May 2007. 260. “Case Approach to Improving Virologic Response, Early and Sustained”, Mesa AZ, August 2007. 261. “Case Approach to Improving Virologic Response, Early and Sustained”, Las Vegas NV, August 2007. 262. “Emergency Data in the Management of HBV”, Chronic Liver Disease Foundation, Santa Ana CA, October 2007. 263. “Case Approach to Improving Virologic Response, Early and Sustained”, San Antonio TX, November 2007. 264. “NASH, Clinical Manifestations and Treatment”, Topics and Advances in Internal Medicine, San Diego CA, March 2008. 265. Chronic Liver Disease Teleconference Series, CLDF, April 2008. 266. CRRT Meeting, San Diego CA, April 2008. RESEARCH STUDIES: 1. A Phase III, Open-Label Randomized, Multicenter Trial to Determine the Efficacy of Recombinant-Methionyl Interferon Consensus (r-metIFN-Con1) in Patients with Chronic Hepatitis C Virus After Prior Treatment with r-metIFN-con1 or Interferon Alpha 2-b Recombinant. 10/1996 2. An Open Labeled Trial of a Sliding Scale, High-dose of Intron A + Ribavirin for Treatment of Patients With Interferon-Refractory on Interferon-Relapsed Chronic Hepatitis C. 04/1997 3. An Open Labeled Trial of Intron A + Ribavirin for Treatment of Patients with Interferon-Refractory or Interferon-Relapsed Chronic Hepatitis C. 04/1997 4. An Open Label Trial of Prolonged, High-dose Interferon Alfa-2a (Roferon A) Therapy in Patients with Chronic Hepatitis C Virus. 05/1997 5. Randomized, Double-Blind, Multicenter Comparison of the Effects and Safety of Three Dose Levels of VPA-985 and Placebo in the Treatment of Patients with Hyponatremia. 02/1998 6. Intron A+ Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously Treated with Interferon (Sliding Scale). 02/1998 7. Intron A + Ribavirin for Treatment of Patients with Chronic Hepatitis C Not Previously Treated with Interferon. 02/1998 8. An Open Label Study of Neoral as a Primary Immunosuppressant Therapy in Transplant Patients who are Unable to Maintain Satisfactory Immunosuppression on Program (Tacrolimus). 02/1998 9. A Phase III, Randomized, Multicenter, Efficacy and Safety Study Comparing the Combination of Pegylated Interferon Alpha-2a and Ribavirin with Rebetron in the Treatment of Patients with Chronic Hepatitis C Infection. 10/1998 10. A Phase II/III Double-Blind Study of the Safety and Antiviral Activity of Ribavirin with Interferon -2b compared to Interferon -2b Alone for the Treatment of Patients with Hepatitis C and Co-Infected with HIV. 12/1998 11. A Double Blind Randomized, Placebo Controlled Study of Adefovir Dipivoxil for the Treatment of Chronic Hepatitis B. 01/1999 12. The complications of Liver Biopsy in HIV Infected Individuals. 06/1999 13. A Randomized Trials of Sliding Scale Rebetron vs Induction Rebetron in Naïve Patients with Chronic Hepatitis C. 06/1999 14. A Randomized Trial of High Dose Rebetron vs. Induction/Rebetron in Interferon-Refractory or Interferon-Relapse Patients with Chronic Hepatitis C. 7/1999 15. A Phase III, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study of The Effects of a Somatostatin Analogue-Lanreotide-As Adjuvant to Endoscopic Band Ligation of Patients with Acute Bleeding From Oesophageal Varices Secondary to Cirrhosis and Portal Hypertension. 08/1999 16. Daily Infergen Therapy for Patients with Chronic Hepatitis C Virus who have Failed Previous Interferon Treatment. 08/1999 17. High-dose Intron A + Ribavirin for Treatment of Patients with Interferon Refractory of Interferon-Relapsed Chronic Hepatitis C. 08/1999 18. An Open-Label, Randomized, Parallel-Group Study Comparing the Effectiveness of PROCRIT (Epoetin alfa) Administered Once Weekly Versus Standard of Care in Hepatitis C Patients Treated with Combination Ribavirin/Interferon -2b. 09/1999 19. A Phase III, Randomized, Multicenter, Efficacy and Safety Study Examining the Effects of the Duration of Treatment and the Daily Dose of Ribavirin in Patients with Chronic Hepatitis C Virus Infection Treated with the Combination of Pegylated-Interferon -2a and Ribavirin. 09/1999 20. A Randomized, Open-Label, Multicenter, Efficacy and Safety Study of Pegasys plus Ribavirin, Pegasys plus Cellcept, Pegasys plus Amantadine, or Pegasys plus Amantadine plus Ribavirin in Patients with Chronic-HCV Infection who Relapsed on Rebetron Therapy. 10/1999 21. Interferon ALFACON-1 (Infergen) for the Treatment of Chronic Hepatitis C In Patients Coinfected with Human Immunodeficiency Virus. 12/1999 22. A Randomized, Partially-Blinded, Multicenter, Phase II, Study Investigating the Efficacy and Safety of Pegasys and Pegasys with Ribavirin in Treatment of Naïve Patients with Chronic Hepatitis Co-infected with Human Immunodeficiency Virus. 2000 23. A Phase III, Double-Blind, Multicenter, Randomized, Placebo-Controlled Study of the Effects of a Somatostatin Analogue-Lanreotide-as an Adjuvant to Endoscopic Band Ligation of patients with Acute Bleeding from Esophageal Varices Secondary to Cirrhosis and Portal Hypertension. 2000 24. A Pilot Study of Sliding Scale Rebetron vs. Induction/Rebetron in Naïve Patients with Chronic Hepatitis. 02/2000 25. A Prospective Controlled Study of the Clinical Efficacy of Albumin Dialysis using the Molecular Adsorbent Recirculating Systems (MARS) for the Treatment of Patients with Hepatic Encephalopathy. 03/2000 26. A Protocol for Re-Treatment with the Combination of Peginterferon Alfa-2b and Ribavirin for Patients with Chronic Hepatitis C in Original Study NV 15942 who Relapsed Virologically After Completing 24 Weeks of Treatment. 09/2000 27. A Prospective Randoized, Multicener, Open-Label Comparative Safety Study of Pegasys vs. Pegasys Plus Ribavirin Treatment vs. a Twelve Week Treatment Delay in Patients with Chronic Hepatitis C. 12/2000 28. Emergency Use of the Molecular Adsorbent Recirculated Szystem (MARS) for the Treatment of One Patient with Cholestasis (post hepatic encephalopathy protocol participation. 01/2001 29. A Phase III Study of the Safety and Antiviral Activity of Entecavir vs. Lamivudine in Adults with Chronic Hepatitis B Infection who are Positive for Hepatitis B E Antigen. 01/2001 30. Emergency use of additional MARS Treatments for One patient, DW, for Grade III and IV Encephalopathy. 11/2001. 31. A Prospective, Randomized, Phase II Study, Investigating the Safety and Efficacy of Pegasys + Ribavirin Versus Pegasys + Week 12 Addition of Ribavirin in Patients With HIV/HCV Coinfection: Nonresponders or Relapsers to Interferon Monotherapy or in Combination With Ribavirin. 12/2001 32. Emergency Use of the MARS Protocol for One Patient, G.S., for End Stage Liver Disease. 2/2002 33. Assessment of Driving Behavior of Patients with End Stage Liver Disease. 09/2002 - current 34. Emergency use of the MARS System for One Patient A.S. 1/2003 35. Neuropsychological Profile of Liver Transplant Candidates. 03/2003 – current 36. Depression, Anxiety, Fatigue, Sleep and Substance Abuse in a Clinical Hepatology Population. 04/2003 - current 37. A Prospective, Open-label Dose Escalation Study Evaluating the Saftey and Efficacy of Infergen Administration by Continuous Delivery Using a Subcutaneous Pump in Combination with Daily Oral Ribavirin in Patients Infected with Hepatitis C Virus who are Treatment Naïve or Peginterferon-alfa Plus Ribavirin or Interferon-alfa Plus Ribavirin Nonresponders. 06/2003 38. UCSD Adult Hepatology and Liver Transplant Clinic Database. 06/2003 – current 39. Epidemiological Study: A Descriptive Review of the Treatment of HIV/HCV Co-Infection. 06/2003 40. A Randomized, Double Blind Trial of LdT (Telbivudine) versus Lamivudine in Adults with Compensated Chronic Hepatitis B. 11/2003 41. The Influence of Chronic Liver Disease on Psychosocial Factors Associated with Quality of Life and Adherence. 11/2003 – current 42. NIH – A National Registry of Subjects with Hepatocellular Carcinoma. 11/2003 - current 43. Safety and Tolerability of Sho-saiko-to (SST) in Patients with Compensated Cirrhosis due to Chronic HCV Infection: A Doublie blinded Phase II Trial. 11/2003 – 2008 44. Validation of a New Method for Grading Hepatic Encephalopathy. 12/2003 – current 45. NIH - Pediatric Trials in Non-Alcoholic Steatohepatitis (NASH) 2004 – current 46. Review of Patients with HIV and Liver Disease. 2004 – current 47. A Randomized, Double Blind, Multicenter Study to Compare the Safety and Efficacy of Viramidine to Ribavirin in Treatment-Naïve Patients with Chronic Hepatitis C. 01/2004 – current 48. Phase 2, Randomized, Dose-Ranging, Open-label Study of the Safety and Tolerability of Consensus Interferon-Alpha (CIFN) plus Interferon Gamma-1b (IFN-γ 1b) with or without Ribavirin (RBV) in the Treatment of Patients with Chronic Hepatitis C who are Non-responders to PEG-IFN-α (2a or 2b) plus RBV. 02/2004 49. The Role of Real Time Depression Screening During HCV Therapy with Interferon. 02/2004 – current 50. The UCSD Liver Center Serum & Tissue Repository of Subjects with Non-Alcoholic Fatty Liver Disease (NAFLD). 02/2004 – current 51. NIH: A Multi-Center Group to Study Acute Liver Failure and The Safety And Efficacy of N-Acetylcysteine (NAC) in the Treatment of Acute Liver Failure (ALF) Not Caused by Acetaminophen in Adult patients. 03/2004 - current 52. A Prospective, Randomized, Open-label Study Evaluating the Viral Kinetics & Pharmacokinetics of Pegasys Plus Copegus and PEG-Intron plus Rebetol in Interferon-naïve Patients with Chronic Hepatitis C. 03/2004 – current 53. Evaluation of Acute Variceal Bleeding and Rebleeding Treatments. 04/2004 – current 54. A Phase 3, Randomized, Open-Label Study of the Safety and Efficacy of Two Dose Levels of Interferon Alfacon-1 (Infergen, CIFN) plus Ribavirin Administered Daily for 48 Weeks versus No-treatment in Hepatitis C Infected Patients Who Are Nonresponders to Previous Pegylated Interferon Alfa plus Ribavirin Therapy. 05/2004 – current 55. A Randomized, Double Blind Trial of Telbivudine (LdT) versus Lamivudine in Adults with Decompensated Chronic Hepatitis B and Evidence of Cirrhosis. 05/2004 – current 56. Sampling Variations in Liver Biopsies. 08/2004 – current 57. A Double-Blind, Placebo-Controlled, Randomized Phase III Study of Intravenous Terlipressen in Patients with Hepatorenal Syndrome Type 1. 09/2004 58. A Prospective, Multicenter, Open-label, Comparative Efficacy Study of Pegasys® Plus Copegus® in Treatment Naïve Latino Patients with Chronic Hepatitis C-Genotype 1, as Compared to Treatment-Naïve Non-Latino Caucasian Patients with Chronic Hepatitis C Genotype 1. 11/2004 - current. 59. Psychiatric Symptoms and PPI in HCV Patients. 03/2005 – current 60. A Phase 3 Randomized, Open-label Study of the Safety and Efficacy of Two Dose Levels of Daily Interferon Alfacon-1 plus Ribavirin in Hepatitis C Infected Patients Who Failed to Achieve Virologic Response After {Previous Pegylated Interferon Alfa plus Ribavirin Therapy and during at Least 24 Weeks of No Treatment in IRHC-001. 04/2005 – 2008 61. A randomized, double-blind study of GT267-004 versus Vancomycin and GT267-004 versus Metronidazole in patients with C Difficile-associated diarrhea. 05/2005 – current 62. Psychiatric Symptoms and the Hypothalamic-Pituitary-Adrenal Axis in Hepatitis C Patients. 05/2005 – current 63. NIH –NeuroAIDS (NIDA): Effects of Methamphetamine and HCV 09/2005 – current 64. A Phase I Prospective, Longitudinal Feasibility Trial of Safety, Tolerance and Efficacy of SEPET in Patients with Acute Exacerbation of Chronic Liver Disease. 11/2005 – 2008 65. A Phase 2, Randomized, Active-Controlled Study of the Safety and Efficacy of Ammonul® (Sodium Benzoate) Injection 10%/10% in Patients with Grade III to IV Hepatic Encephalopathy. 12/2005 – current 66. An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-sponsored Telbivudine Studies. 01/2006 – current 67. A Randomized, Double-Blind, Placebo-Controlled, Multi-Center, Time-Lagged, Parallel, Multiple-Dose, Escalating-Dose Study to Assess Safety/Tolerability, Pharmacokinetic and Pharmacodynamic Profiles Following Administration of NIM811 in Patients with Viral Hepatitis C Genotype 1 (HCV-1). 02/2006 – current 68. A Multi Center, Randomized, Double-Blind, Placebo-Controlled Trial to Evaluate the Efficacy, Safety and Tolerability of Rifaxamin 550 mg BID for 6 Months in Preventing Hepatic Encephalopathy. 04/2006 – current 69. Assessment of Hepatic Encephalopathy Scoring Systems. 04/2006 – current 70. A Randomized, Multicenter, Double-Blinded, Phase IV Study Evaluating the Efficacy (as measured by Sustained Virological Response) and Safety of 360 g Induction Dosing of Pegasys in Combination with Higher Copegus Doses in Treatment-navie Patients with Chronic Hepatitis C Genotype 1 Virus Infection of High Viral Titer and Baseline Body Weight Greater than or Equal to 85 kg. 2006 – current 71. The Early Use of Sanvar® with Endoscopic Treatment for the Control of Acute Variceal Bleeding Due to Portal Hypertension. 2006 – current 72. Satavaptan in the Prevention of Ascites Recurrence: a double-blind, randomised, parallel-group comparison of satavaptan at 5 to 10 mg daily versus placebo with concomitant diuretics in patients with recurrent ascites due to cirrhosis of the liver. 2006 – current 73. A Phase II, Randomized, Multicenter, Double-Blinded Study Evaluating the Safety and Tolerability of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given In Combination with Pegasys With or Without Copegus Versus the Currently Approved Combination of Pegasys and Copegus in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection. 2006 – current 74. A Randomized, Multicenter, Double Blinded, Phase IV Study Comparing the Safety and Efficacy of Pegasys® 180ìg plus Copegus® 1000 or 1200 mg to the Currently Approved Combination of Pegasys® 180ìg plus Copegus® 800 mg in Interferon-naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection Coinfected with Human Immunodeficiency Virus (HIV-1). 2006 – current 75. An Open Label Trial of Telbivudine (LdT) in Adults with Chronic Hepatitis B Previously Treated in Idenix-Sponsored Telbivudine Studies. 2006 – current 76. A Phase II, Randomized, Double-Blinded, Multicenter, Dose Finding Study Evaluating the Efficacy and Safety of the HCV Polymerase Inhibitor Prodrug (RO4588161) When Given in Combination with Pegasys® and Copegus® versus the Currently Approved Combination of Pegasys® and Copegus® in Treatment-Naive Patients with Chronic Hepatitis C Genotype 1 Virus Infection. 2007 – current 77. A Phase II, Randomized, Controlled Trial of The Safety And Efficacy Of S-Adenosyl-L-Methionine Disulphate P-Toluene-Sulfonate (SAMe) In Reducing Serum Alpha-Fetoprotein (AFP) In Patients With Hepatitis C And Moderately Elevated AFP. 2007 – current 78. A Randomized, Double-Blind Study to Assess the Efficacy and Safety of Prophylactic use of Maribavir versus Oral Ganciclovir for the Prevention of Cytomegalovirus Disease in Recipients of Orthotopic Liver Transplants. 2007 – current 79. A Phase 2 Rollover Protocol of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects Enrolled in the Control Group (Group A) of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Who do not Achieve or Maintain an Undetectable HCV RNA Level Through Sustained Viral Response. 2007 – current 80. Randomized, Observational Study of Entecavir to Assess Long-term Outcomes Associated with Nucleoside/Nucleotide Monotherapy for Patients with Chronic HBV Infection: The REALM Study. 2007 – current 81. Validation of the Acute Physiology & Chronic Health Evaluation (APACHE II) and the Sepsis-related Organ Failure Assessment (SOFA) in Patients Hospitalized with End Stage Liver Disease (ESLD). 2007 – current 82. UCSD Adult Hepatology and Liver Transplant Clinic Database (Renewal of IRB # 030864X) 2007 – current 83. A Phase 2 Study of Telaprevir (VX-950) in Combination with Peginterferon Alfa-2a (Pegasys®), and Ribavirin (Copegus®) in Subjects with Genotype 1 Hepatitis C Who Have Not Achieved Sustained Viral Response with a Prior Course of Interferon-Based Therapy. 2007 – current 84. Depression, Anxiety, Fatigue, Sleep, and Substance Abuse in a Clinical Hepatology Population. 2007 – current 85. A Phase 3, Randomized, Multi-Center Study to Evaluate the Efficacy and Safety of Albumin Interferon Alfa-2b (alb-IFN) in Combination with Ribavirin Compared with Peginterferon Alfa-2a (PEGASYS or PEG-IFNƒ¿2a) in Combination with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 1. 2007 – current 86. Review of HBV/HIV Co-infected patients. 2008 – current 87. A Randomized, Open-Label, Multicenter Study Examining the Effects of 24 Versus 48 Weeks of Combination Therapy with PEGASYS® (Peginterferon alfa-2a 40KD) plus COPEGUS® (Ribavirin) on Sustained Virological Response in Patients with Chronic Hepatitis C, Genotype 2 or 3 who do not Achieve a Rapid Viral Response. 2008 – current 88. A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of Type 2 diabetic patients with nonalcoholic steatohepatitis (NASH). 2008 – current 89. A double-blind, randomized, placebo-controlled, parallel group study of rimonabant 20 mg daily for the treatment of non-diabetic patients with nonalcoholic steatohepatitis (NASH). 2008 – current 90. A Phase 3 Study of 2 Dose Regimens of Telaprevir in Combination with Peginterferon Alfa 2a (Pegasys®) and Ribavirin (Copegus®) in Treatment-Naïve Subjects with Genotype 1 Chronic Hepatitis C. 2008 – current 91. Prospective observational study on predictors of early on-treatment response and sustained virological response in a cohort of treatment naïve HCV-infected patients treated with pegylated interferons. (Prophesys 3). 2008 – current 92. A Multi-Center Group to Study Acute Liver Failure. National Institutes of Health. 2008 - current SUBMITTED PUBLICATIONS/MANUSCRIPTS IN PREPARATION: 1. Kostman J, Torres M, Prokupek, D, Brau N, Bonacini M, Giffen C, Smith Jfrost K, Hassanein T. Results of a Multi-Center Randomized, Double Blind, Controlled Trail of Interferona-2b and Ribavirin Combination Therapy in Persons Co-Infected with Hepatitis C Virus and Human Immunodeficiency Virus. 2. Ilyas, JA, Zileri Dal Verme L, Pozza R, Oliver DL, Barakat F, Barber E, Mathews WC, Hassanein TI. Barriers to HCV therapy in HIV/HCV co-infected patients. 3. Yuko, K, Sirlin C, Alpert E, Hassanein TI, Rose SC. Super-paramagnetic iron oxides and low molecular weight gadolinium chelates are synergestic for direct visualization of advanced liver fibrosis. PUBLICATIONS IN PRESS: JOURNAL PUBLICATIONS: 1. Hassanein T. Incidence and etiology of chronic abdominal pain in patients admitted to the Medical Wards of Alexandria University. Master Thesis, Library of Alexandria University, 1987. 2. Rabinovitz M, Zajko AB, Hassanein T, Shetty B, Bron KM, Schade RR, Gavaler JS, Block G, Van Thiel DH, Dekker A. Diagnostic Value of Brush Cytology in the Diagnosis of Bile Duct Carcinoma: A Study in 65 Patients with Bile Duct Strictures. Hepatology 1990;12:747-752. 3. Sakr MF, Hassanein TI, Zetti GM, Van Thiel DH. FK 506 Ameliorates the Hepatic Injury Associated with Ischemia. Life Sciences 1990;47:687-691. 4. Hassanein T, Perper JA, Tepperman L, Starzl TE, Van Thiel DH. Liver Failure Occurring as a Component of Exertional Heatstroke. Gastroenterology 1991;100:1442-1447. 5. Hassanein TI, Gavaler JS, Fishkin D, Gordon R, Starzl TE, Van Thiel DH. Does the Presence of a Measurable Blood Alcohol Level in a Potential Organ Donor Affect the Outcome of Liver Transplantation? Alcoholism: Clinical and Experimental Research 1991;15:300-304. 6. Sakr MF, Zetti GM, Hassanein TI, Farghali H, Nalesnik MA, Gavaler JS, Starzl TE, Van Thiel DH. FK 506 Ameliorates the Hepatic Injury Associated with Ischemia and Reperfusion in Rats. Hepatology 1991;13:947-951. 7. Sakr MF, Zetti GM, Farghali H, Hassanein TH, Gavaler JS, Starzl TE, Van Thiel DH. Protective Effect of FK 506 against Hepatic Ischemia in Rats. Transplantation Proceedings 1991;23:340-341. 8. Hassanein T, Razack A, Gavaler JS, Van Thiel DH. Heatstroke: Its Clinical and Pathological Presentation, with Particular Attention to the Liver. The American Journal of Gastroenterology 1992;87:1382-1389. 9. El-Ashmawy L, Hassanein T, Gavaler JS, Van Thiel DH. Prevalence of Hepatitis C Virus Antibody in a Liver Transplantation Population. Digestive Diseases and Sciences 1992;37:1110-1115. 10. Sakr M, Hassanein T, Gavaler J, Abu-Elmagd K, Fung J, Gordon R, Starzl T, Van Thiel D. Cytomegalovirus Infection of the Upper Gastrointestinal Tract Following Liver Transplantation-Incidence, Location, and Severity in Cyclosporine- and FK506-Treated Patients. Transplantation 1992;53:786-791. 11. Wright HL, Bou-Abboud CF, Hassanein T,Block GD, Demetris AJ, Starzl TE Van Thiel DH. Disease Recurrence and Rejection Following Liver Transplantation for Autoimmune Chronic Active Liver Disease. Transplantation 1992;53:136-139. 12. Hassanein T, Schade R. Hemochromatosis. Gastroenterology and Endoscopy News. Oct. 1993;22-28. 13. Hassanein TI, Shetty B, Gavaler JS, Sakr MF, Sheahan DG, Rinaldo C, Van Thiel DH. The timing, location and histologic characterization of upper gastrointestinal cytomegalovirus infection occurring in a liver transplant population. European Journal of Gastroenterology & Hepatology 1993;5:1021-1027. 14. Gurakar A, Fagiuoli S, Hassanein T, Kingery L, Wright HI, Ersoz S, Caraceni P, Gavaler JS, Van Thiel DH. Prophylactic alpha-interferon therapy following liver transplantation: does it prevent allograft infection? European Journal of Gastroenterology & Hepatology 1994;6:429-432. 15. Gurakar A, Fagiuoli S, Gavaler JS, Hassanein T, Jabbour N, Wright HI, Deal SA, Shah A, Brown M, Carr BI Van Thiel DH. The use of granulocyte-macrophage colony stimulating factor to enhance hematologic parameters of patients with cirrhosis and hypersplenism. Journal of Hepatology 1994;21:582-586. 16. Appasamy R, Bryant J, Hassanein T, Van Thiel DH, Whiteside TL. Effects of Therapy with Interferon alfa on Peripheral Blood Lymphocyte Subsets and NK Activity in Patients with Chronic Hepatitis C. Clinical Immunology and Immunopathology 1994;73:350-357. 17. Gurakar A, Fagiuoli S, Hassanein T, Wright HI, Balkan M, Frezza E, Todo S, Starzl TE, Van Thiel DH. Is rejection a diffuse or localized process in small-bowel transplantation? Surgical Endoscopy 1994;8:762-764. 18. Hassanein T, Schade RR, Soldevilla-Pico C, Tabasco-Minguillan J, Abu-Elmagd K, Furukawa H, Kadry Z, Demetris A, Tzakis A, Todo S. Endoscopy is Essential for Early Detection of Rejection in Small Bowel Transplant Recipients. Transplantation Proceedings 1994;26:1414-1415. 19. Hassanein T, Schade R, Soldevilla-Pico C, Tabasco-Minguillan J, Abu-Elmagd K, Furukawa H, Kadry Z, Demetris A, Tzakis A Todo S. Clinical and Endoscopic Features of Rejection in Small Bowel Transplant Recipients. Transplantation Proceedings 1994;26:1413. 20. Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Major Gastrointestinal Bleeding Occurring After Liver Transplantation. The Journal of the Oklahoma State Medical Association 1995;88:114-118. 21. Van Thiel DH, Hassanein T,Gurakar A, Caraceni P, Nadir A, Wright HI. The Polka Dot Liver and Spleen: A Case Report. The Journal of the Oklahoma State Medical Association 1995;88:7-10. 22. Van Thiel DH, Hassanein T. Assessment of Liver Function: The Current Situation. The Journal of the Oklahoma State Medical Association 1995;88:11-16. 23. Gurakar A, Hassanein T, Van Thiel DH. Right Diaphragmatic Paralysis Following Orthotopic Liver Transplantation. The Journal of the Oklahoma State Medical Association 1995;88:149-153. 24. Van Thiel DH, Nadir A, Hassanein T, Wright HI. Simultaneous Right-sided Volume Overload and Left-sided Hypovolemia in a Man with Massive Ascites and a Hydrothorax. The American Journal of Gastroenterology 1995;90:478-481. 25. Nadir A, Nadir F, Hassanein T, Gurakar A, Wright HI, Van Thiel DH. Acute Relapsing Pancreatitis Induced with Ursodeoxycholic Acid Therapy. The Journal of the Oklahoma State Medical Association 1995;88:295-298 26. Van Thiel DH, Caraceni P, DeMaria N, Nadir A, Hassanein T, Nadir F. Panhypopituitarism in Two Cirrhotics: Clinical Presentation and Liver Disease Associations. The Journal of the Oklahoma State Medical Association 1995;88:299-304. 27. Knowdley KV, Hassanein T, Kaur S, Farrell FJ, Van Thiel DH, Keeffe EB, Sorrell MF, Bacon BR, Weber FL, Tavill AS. Primary Liver Cancer and Survival in Patients Undergoing Liver Transplantation for Hemochromatosis. Liver Transplantation and Surgery 1995;1:237-241. 28. Colantoni A, DeMaria N, Hassanein TI,Van Thiel DH. Management of Hepatitis B Pre- and Post OLTx: a Review and a Look to the Future. Viral Hepatitis 1995;1:157-170. 29. Hassanein T, Van Thiel DH, Guraker A. Gut Permeability. Update in intensive care and emergency medicine. Springer-Verlag (Heidelberg, Germany). 1995;129-144. 30. Hassanein T, Van Thiel DH. Biochemical abnormalities in liver disease. In: Investigations in Hepatology. Bailliere's Clinical Gastroenterology. Dec 1995;9(4):679-688. 31. Bellary S, Hassanein T, Van Thiel DH. Liver transplantation for Wilson’s disease. Journal of Hepatology 1995;23:373-391. 32. Van Thiel DH, Caraceni P, Molloy PH, Hassanein T, Kania RJ, Gurakar A Friedlander L. Chronic hepatitis C in patients with normal or near normal alanine aminotransferase levels: the role of interferon alfa2b therapy. Journal of Hepatology 1995;23:503-508. 33. Fagiuoli S, Gurakar A, Hassanein T, Wright HI, Van Thiel DH. Liver Resection and Transplantation. In: Consultations in Gastroenterology. Snape W (ed). W.B. Saunders New York 1996:828-842. 34. Van Thiel DH, Colantoni A, De Maria N, Fagiuoli S, Gasbarrini A, Hassanein T. Liver transplantation in the United States: Current problems and future goals. Ital J Gastroenterol 1996;28:169-175. 35. Ichida T, Van Thiel DH, Hassanein T. The Medical Management of Hepatocellular Carcinoma (HCC) in Japan: A Review with Implications for HCC Seen in the West. Hepato-Gastroenterology 1996;43:1575-1583. 36. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Caraceni P, De Maria, N, Nadir A. Liver Transplantation after an Acute Episode of Spontaneous Bacterial Peritonitis. Hepato-Gastroenterology 1996;43:1584-1588. 37. Hassanein T,Colantoni A, De Maria N, Van Thiel DH. Interferon-alfa 2b improves short-term survival in patients transplanted for chronic liver failure caused by hepatitis B. Journal of Viral Hepatitis 1996;3:333-340. 38. Friedlander L, Van Thiel DH, Faruki H, Molloy PJ, Kania RJ, Hassanein T. New Approach to HCV Treatment Recognition of Disease Process as Systemic Viral Infection Rather than as Liver Disease. Digestive Diseases and Sciences 1996;41:1678-1681. 39. Sandford SL, Colantoni A, De Maria N, Hassanein T, Van Thiel D, Tarter RE. Neuropsychological impairment in a patient with a normal liver and long-standing portacaval anastomosis: studies obtained before and after liver transplantation. European Journal of Gastroenterology & Hepatology 1996;8:919-923. 40. Hassanein T, Wahlstrom HE. The role of Immune Modulators in the Treatment of Viral Hepatitis. Antiviral Therapy. 1996;1:84-89. 41. Tan HP, Wahlstrom HE, Zamora JU, Hassanein T. Aureobasidium Pneumonia in a Post Liver Transplant Recipient: A Case Report. Hepato-Gastroenterology 1997;44:1215-1218. 42. Hassanein TI,Wahlstrom HE, Zamora JU, Van Thiel DH. Conventional Care of Fulminant Hepatic Failure: Medical and Surgical Aspects. Therapeutic Apheresis 1997;1:33-37. 43. Bayraktar Y, Bayraktar M, Gurakar A, Hassanein TI, Van Thiel DH. A Comparison of the Prevalence of Autoantibodies in Individuals with Chronic Hepatitis C and Those with Autoimmune Hepatitis: The Role of Interferon in the Development of Autoimmune Diseases. Hepato-Gastroenterology 1997;44:417-425. 44. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T,Faruki H. A preliminary experience with GM-CSF plus interferon in patients with HBV and HCV resistant to interferon therapy. Journal of Viral Hepatitis 1997;4:101-106. 45. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T,Wahlstrom HE, Faruki H. Lamivudine Treatment of Advanced and Decompensated Liver Disease due to Hepatitis B. Hepato-Gastroenterology 1997;44:808-812. 46. Colantoni A, Hassanein T, Idilman R, Van Thiel DH. Liver Transplantation for Chronic Viral Liver Disease. Hepato-Gastroenterology 1998;45:1357-1369. 47. Buck M, Kim DJ, Houglum K, Hassanein T, Chojkier M. c-Myb modulates transcription of the -smooth muscle acting gene in activated hepatic stellate cells. Am. J. Physiol. Gastrointest. Liver Physiol. 2000;278:G321-G328. 48. Lonergan JT, Behling C, Pfander H, Hassanein T, Mathews WC. Hyperlactatemia and Hepatic Abnormalities in 10 Human Immunodeficiency Virus Infected Patients Receiving Nucleoside Analogue Combination Regimens. Clinical Infectious Diseases 2000;31:162-6. 49. Rose S, Pretorius D, Nelson T, Kinney T, Huynh T, Roberts A, Valji K, D’Agostino H, Oglevie S, James G, Hassanein T, Hart M, Orloff M. Adjunctive 3D US for Achieving Portal Vein Access During Transjugular Intrahepatic Portosystemic Shunt Procedures. JVIR 2000. 50. Rose, SC, Hassanein TI, Easter DW, Gamagami RA, Bouvet M, Pretorius DH, Nelson TR, Kinney TB, James GM. Value of three dimensional US for optimizing guidance for ablating focal liver tumors. Journal of Vascular and Interventional Radiology 2001;12:507-15. 51. Allen JW, Hassanein T, Bhatia SN. Advances in Bioartificial Liver Devices. Hepatology 2001 (3);34:447-455. 52. Rose S, Andre M, Roberts A, Kinney T, Valji K, Ronaghi A, Hassanein T, Lavine J, Hart M, Khanna A. Integral role of interventional radiology in the development of a pediatric liver transplantation program. Pediatric Transplantation 2001;5:331-338. 53. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Serum Aminotransferase Levels and Platelet Counts as Predictors of Degree of Fibrosis in Chronic Hepatitis C Virus Infection. Amer Jour of Gastro 2002;96:3142-3146. 54. Robin C. Hilsabeck, William Perry, Tarek I. Hassanein. Neuropsychological Impairment In patients with Chronic Hepatitis C. Hepatology 2002:440-446. 55. Stange J, Hassanein T, Mehta R, Mitzner S, Bartlett. The Molecular Adsorbents Recycling System as a Liver Support System Based on Albumin Dialysis: A Summary of Preclinical Investigations, Prospective, Randomized, Controlled Clinical Trail, and Clinical Experience from 19 Centers. Artificial Organs: 2002;26(2):103-110. 56. Rose S, Behling C, Roberts A, Pretorius D, Nelson T, Kinney T, Masliah E, Hassanein T. Main Portal Vein Access in Transjugular Intrahepatic Portosystemic Shunt Procedures: Use of the Three-dimensional Ultrasound to Ensure Safety. J Vasc Interv Radiol 2002: 267-273. 57. Rose SC, Hassanein TI, Bouvet M, Hart ME, Khanna A, Saville MW. Delivery of radiofrequency ablation probes to the targeted liver malignancy; using all the players on the field. J Vase Interv Radiol. 2002 Oct:13(10):1060-1 58. Stange J, Hassanein TI, Mehta R, Mitzner SR, Bartlett RH. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: a summary of preclinical investigations, prospective, randomized, controlled clinical trial, and clinical experience from 19 centers. Artif Organs 2002 Feb 26(1):103-110 59. Dieterich D, Wasserman R, Brau N, Hassanein T, Bini, E, Bowers, P, Sulkowski M. Once-weekly Epoetin Alfa Improves Anemia and Facilitates Maintenance of Ribavirin Dosing in Hepatitis C Virus-Infected Patients Receiving Ribavirin Plus Interferon Alfa. Am J Gastroenterol 2003;98:2491-2499. 60. Diago M, Hassanein T, Rodés J, Ackrill AM, Sedarati F. (Letter) Optimized Virologic Response in Hepatitis C Virus Genotype 4 with Peginterferon-α2a and Ribavirin. Ann Intern Med 2004;140:72-73. 61. Zeh N, Rossi SS, Hofmann AF, Steinbach JH, Hagey LR, Oliver D, Stange J, Hassanein T. The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver Int. 2003;23 Suppl 3:34-8. 62. Hassanein T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed acute liver injury: possible impact of albumin dialysis on hospitalization costs. Liver Int. 2003;23 Suppl 3:61-5. 63. DiBisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok AS, Hussain KB, Gish R, VanThiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related Hepatocellular carcinoma in the United States: influence of ethnic status. Am J Gastroenterol, 2003 Sep;98(9);2060-3. 64. Hilsabeck RC, Hassanein T, Carlson MD, Ziegler EA, Perry W. Cognitive functioning and psychiatric symptomatology in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2003 Sep;9(6):847-54. 65. Hilsabeck RC, Hassanein TI. Hepatitis C & Cognitive Impairment. The HCV Advocate Medical Writers’Circle. August 2003 66. Kinney TB, Ferrara SL, Miller FJ, Roberts AC, Hassanein T. Transjugular intrahepatic portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in a patient with cirrhosis. J Vasc Interv Radiol. 2004 Jan;15(1 Pt 1):85-9. 67. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Treho-Estrada R, Horta E, Vale A, Wintfeld N, Green J. The impact of peginterferon alfa-2a plus ribavirin combination therapy on health-related quality of life in chronic hepatitis C. J Hepatol, 2004 Apr;40(4):675-81. 68. Radhakrishna Pillai G, Srivastava AS, Hassanein T, Chauhan DP, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Letters 2004 May 28;208(2):163-70. 69. Sullivan SD, Jensen DM, Bernstein DE, Hassanein T, Foster GR, Lee SS, Cheinquer H, Craxi A, Cooksley G, Klaskala W, Pettit K, Patel KK, Green J. Cost-Effectiveness of Combination Peginterferonalpha-2a and Ribavirin Compared With Interferon alpha-2b and Ribavirin in Patients With Chronic Hepatitis C. Am J Gastroenterol. 2004 Aug:99(8):1490-6 70. Hassanein T. Mitochondrial dysfunction in liver disease and organ transplantation. Mitoch 166, 2004 13:19pp.1-12. 71. Hilsback RC, Hassanein TI, Ziegler EA, Carlson MD, Perry W. Effect of Interferon-alpha on cognitive functioning in patients with chronic hepatitis C. J Int Neuropsychol Soc. 2005 Jan;11(1):16-22. 72. Fredrick RT, Hassanein TI. Role of growth factors in the treatment of patients with HIV/HCV coinfection and patients with recurrent hepatitis C following liver transplantation. J Clin Gastroenterol. 2005 Jan;39 (I Suppl);S14-22. Review. 73. Waris G, Turkson J, Hassanein T, Siddiqui A. Hepatitis C Virus (HCV) Constitutively Activates STAT-3 via Oxidative Stress: Role of STAT-3 in HCV Replication. J Virol 2005 Feb:1659-1580 74. Puckett, JL., Liu J, Bhalla V, Kravetz D, Krinsky ML, Hassanein T, Mittal RK. Ultrasound system to measure esophageal varix pressure: an in vitro validation study. AJP Physiol Gastrointest Liver Physiol . 2005 May;288:G914-9. 75. Hilsabeck, R.C., Hassanein, T.I.,Perry, W. (2005). Biopsychosocial predictors of fatigue in chronic hepatitis C. Journal of Psychosomatic Research, 58, 173-178. 76. Chen J, Lin RK, Hassanein T. Use of Orlistat (Xenical) to Treat Chylous Ascites. J Clin Gastroenterol 2005 Oct: 39(9); 831-833. 77. Perry W, Carlson MD, Barakat F, Hilsabeck RC, Schiehser DM, Mathews C, Hassanein TI. Neuropsychological test performance in patients co-infected with hepatitis C virus and HIV. AIDS. 2005 Oct;19 Supple 3:S79-84 78. Swaminath A, Oliver D, McNeil AC, Hassanein TI.The Influcence of HIV Coinfection on the Natural History of HCV Infection. Current Hepatitis Reports. 20005 Nov: 4(4) 79. Khanna A, Hart M, Nyhan WL, Hassanein T, Panyard-Davis J, Barshop BA. Domino liver transplantation in maple syrup urine disease. Liver Transplantation. 2006 May; 12(5): 876-882 80. Aguirre DA, Behling CA, Alpert E, Hassanein TI, Sirlin CB. Liver fibrosis: noninvasive diagnosis with double contrast material-enhanced MR imaging. Radiology. 2006 May;239(2):425-37. 81. Rutherford A, Daverne T, Hay JE, Murray NG, Hassanein T, Lee WM, Chung RT. Acute Liver Failure Study Group. Influence of high body mass index on outcome in acute liver failure. Clin Gastroenterol Hepatol. 2006 Dec;4(12):1544-9. Epub 2006 Sep 25. 82. Kono Y, Lucidarme O, Choi SH, Rose SC, Hassanein TI, Alpert E, Mattrey RF. Contrast-enhanced ultrasound as a predictor of treatment efficacy within 2 weeks after transarterial chemoembolization of hepatocellular carcinoma. J Vasc Interv Radiology. 2007 Jan;18(1 Pt 1):57-65. 83. Moller HJ, Gronbaek H, Schiodt FV, Holland-Fischer P, Schilsky M, Munoz S, Hassanein T, Lee WM; US Acute Liver Failure Study Group. Soluble CD163 from activated machrophages predicts mortality in acute liver failure. J Hepatol. 2007;47(5):671-6. Epub 2007 Jun 21. 84. Perry W, Hilsabeck RC, Hassanein TI.Cognitive dysfunction in chronic hepatitis C: a review. Dig Dis Sci. 2008. Feb;53(2):307-21. Epub 2007 Aug 17. Review. 85. Hassanein TI,Hilsabeck RC, Perry W. Introduction to the Hepatic Encephalopathy Scoring Algorithm (HESA). Dig Dis Sci. 2008 Feb;53(2):529-38. Epub 2007 Aug 21. 86. Hassanein TI,Tofteng F, Brown RS Jr, McGuire B, Lynch P, Mehta R, Larsen FS, Gornbein J, Stange J, Blei AT. Randomized controlled study of extracorporeal albumin dialysis for hepatic encephalopathy in advanced cirrhosis. Hepatology. 2007 Dec;46(6):1853-62. 87. Hanna RF, Kased N, Kwan SW, Gamst AC, Santosa AC, Hassanein T,Sirlin CB. Double-contrast MRI for accurate staging of hepatocellular carcinoma in patients with cirrhosis. AJR Am J Roentgenol. 2008 Jan;190(1):47-57. 88. Vigil O, Posada C, Woods SP, Atkinson JH, Heatoln RK, Perry W, Hassanein TI, Grant I, Letendre SL, Group TH. Impairments in fine-motor coordination and speed of information processing predict declines in everyday functioning in hepatitis C infection. J Clin Exp Neuropsychol. 2008 Mar 4:1-11. PARTICIPANT: 1. Hadziyannis S, Sette H, Morgan T, Balan V, Diago M, Marcellin P, Ramadori G, Bodenheimer H, Bernstein D, Rizzetto M, Zeuzem S, Pockros P, Lin A, Ackrill A. Peginterferon alfa-2a and Ribavirin Combination Therapy in Chronic Hepatitis C: A Randomized Study of Treatment Duration and Ribavirin Dose. Ann Intern Med 2004;140:346-355. ABSTRACTS: 1. Hassanein TI, Sakr M, Shetty B, Maxxaferro V, Gavaler JS, Van Thiel DH. Hemosiderosis: its impact on subsequent OLTx. American Gastroenterological Association. Gastroenterology 1990;98:A592. 2. Hassanein T, Fishikin D, Gavaler JS, Van Thiel DH. Effect of donor blood alcohol level on transplant outcome. Gastroenterology 1990;98:A592. 3. Hassanein T, Shetty B, Sheahan DG, Rabinovitz M, Reddy S, Schade RR, Gavaler J, Van Thiel DH. The prevalence of helicobacter pylori (Hp) infection is reduced post-OLTx despite the presence of chronic active gastritis. Gastroenterology 1990;98:A56. 4. Shetty B, Hassanein T, Gavaler JS, Van Thiel DH, Rinaldo C, Sheahan D. CMV infection following OLTx. Gastroenterology 1990;98:A123. 5. E, MurrayRabinovitz M, Shetty B, Hassanein T, Schade RR, Gavaler JS, Van Thiel DH, Iwatsuki S, Dekker A. Usefulness of brush cytology in the diagnosis of bile duct carcinoma (BDC) Gastroenterology 1990;98:A305. 6. Sheahan DG, Shetty B, Hassanein T, Iwaki Y, Gavaler JS, Van Thiel DH. Duodenal atrophy in patients with cirrhosis of the liver. Gastroenterology 1990;98:A474. 7. Sakr M, Hassanein T, Zetti G, Van Thiel DH. FK506 Ameliorates the hepatic injury associated with ischemia. Gastroenterology 1990;98:A627. 8. Bou-Abboud CF, Block GD, Hassanein T, Demetrius AJ, Starzl TE, Van Thiel DH. Association of HLA-DR3 with recurrence and rejection after liver transplantation (OLTx) for autoimmune liver disease. Gastroenterology 1990;98:A571. 9. Hassanein T, Gabbour N, Soldevila-Pico C, Nour B, Doddson F, Orons P, Martin M, Zajko A, Schade R, Fung J. The impact of Tips procedure on liver transplantation. Hepatology 1993;18:A333. 10. Yossef SM, Hassanein T, El-Ashmawy, L, Melhem M, Ghaffar YA, Kania R, Van Thiel DH, Whiteside, T. Expression of cytokines mRNA in liver biopsies of patients with chronic hepatitis B infection and patients with schistosomiasis mansoni using in-situ hybridization. Hepatology 1993;18:A263. 11. Kowdley KV, Kaur S, Hassanein T, Farrell FJ, Sorrell MF, Van Thiel DH, Keeffe EB, Bacan BR, Weber FL, Tavill AS. Prevalence of primary liver cancer (PLC) and survival in hereditary hemochromatosis (HHC) patients undergoing orthotopic liver transplantation (OLT). Hepatology 1993;18:A57. 12. Yossef SM, Ghaffar YA, Hassanein T, Salah SA, Molloy PJ, Diamond H, Friedlander L, Whiteside T, Kania R, Van Thiel DH. Serum cytokine levels in Egyptians with schistosomiasis with and without chronic hepatitis B. Hepatology 1993;18:A218. 13. Guraker A, Fagiuoli, Faruki H, Wright H, Hassanein T, Gavaler JS, Van Thiel DH. Failure of prophylactic alpha interferon (IFN) to inhibit HCV replication and disease recurrence following liver transplantation of patients with HCV-Ab positive liver disease. Hepatology 1993;18:A332. 14. Hassanein T, Fagiuoli S, Gurakar , Wright HI, Van Thiel DH. Interferon treatment of anti HCV positive individuals who also have markers of autoimmune liver disease. Gastroenterology 1993;104:A913. 15. Fagiuoli S, Hassanein T, Gurakar A, Cararcini P, Wright HI, Tabasco-Miguillan J, Gavaler JS, Deal S. Liver transplantation for hereditary hemochromatosis (HHC). Gastroenterology 1993;104:A898. 16. Gurakar A, Fagiuoli S, Hassanein T, Ersoz S, Wright HI, Kingery L, Gavaler JS, Van Thiel DH. The role of early initiation of alpha-interferon (IFN) in the prevention of liver allograft reinfection with either HBV or HCV hepatitis. Gastroenterology 1993;104:A711. (Poster) 17. Tabasco-Minguillan J, Mazariegos G, Hassanein T, Gayowski T, Mieles L, Gavaler J, Van Thiel DH, Starzl TE. Results of liver transplantation in American veterans with alcoholic cirrhosis. Gastroenterology 1993;106:A1003. 18. Gurakar A, Balkan M, Fagiuoli S, Hassanein T, Gavaler JS, Wright HI, Van Thiel DH. Anxiety and pain following percutaneous liver biopsy: a comparison of two different needles. Gastroenterology 1993;104A10. 19. Hassanein T, Schade R, Tabasco-Minguilan, Soldevila-Pico C, Abu-Elmagd K, Furukawa H, Kadry Z, Demetris A, Takis A, Todo S. Endoscopy is essential for early detection of rejection in small bowel transplant recipients. The Third International Symposium on Small Bowel Transplantation. November 1993, Paris, France. Transplantation Proceeding 1994;26:1414-1415. (Oral) 20. Hassanein T,Schade R, Soldevila-Pico C, Tabasco-Minguilan J, Abu-Elmagd K, Furukawa K, Kadry Z. Clinical and endoscopic features of rejection in small bowel transplant recipients. The Third International Symposium on Small Bowel transplantation. November, 1993, Paris, France. (Poster) World Congresses of Gastroenterology Transplantation Proceedings 1994;26:1413 (Oral). 21. Hassanein T, Schade R, Baikovitz H, Tabasco-Minguilan J, Furukawa H, Abu-Elmagad K, Todo S. Magnifying endoscopy in small bowel transplant patients. Gastrointestinal Endoscopy 1994;40:P22. (Poster) 22. Hassanein T, Schade R, Belle S, Soldevilla-Pico C, Furukawa H, Abu-Elmagd K, Demetris J, Todo S. Clinical endoscopic features of rejection in small bowel transplant recipients. Gastrointestinal Endoscopy 1994;40:P22. (Poster) 23. Hassanein T, Cicalese L, El-Ashmawy L, Schade R, Whiteside T, Furukawa H, Abu-Elmagd K, Todo S. Decreased IGA levels in the ileal mucosa of small bowel transplant (SBT) grafts. Gastroenterology 1994;106:A697. World Congresses of Gastroenterology. 24. Hassanein T, Schade R, Lasky S, Van Thiel DH. Is interferon an immunosuppressant? Gastroenterology 1004;106:A905. 25. Van Thiel DH, Fagiuoli S, Caraceni P, Wright HI, Gurakar A, Hassanein T. Cryoglobulinemia: A cause for false negative PCR tests in patients with HCV chronic liver disease. Gastroenterology 1994;106:A1002. (Poster) 26. Baddour H, Baker J, Harlan J, Gurakar A, Hassanein T, Fagiuoli S, Caraceni P, Wright HI, Van Thiel DH. High prevalence and intensity of dental disease in patients referred to a liver transplant center. Gastroenterology 1994;106:A862. (Poster) 27. Baddour H, Gurakar A, Hassanein T, Fagiuoli S, Caraceni P, Wright HI, Van Thiel DH. Sinus disease: A source of unsuspected pathology in patients with end stage liver disease. Gastroenterology 1994;106:A862. (Poster) 28. Hassanein T, El-Ashmawy L, Melhem M, Schade RR, Whiteside T. Expression of interferon alpha and gamma genes in liver tissue of patients with chronic hepatitis C infection. Hepatology 1994;20:A621. (Poster) 29. Hassanein T, Finkelstein SD, El-Ashmawy L, Faruki H, Bakkar A, Swalski PA, Whiteside T, Van Thiel D, Schade RR. Effect of immunotherapy on HCV genotype. Hepatology 1994;20:A258. (Poster) 30. Hassanein T, Bronsther O, Tabasco-Minguillan J, Fung J, Schade RR. Thymosin alpha-1 treatment before liver transplantation in a patient with chronic HBV. Hepatology 1994;20:A161. (Poster) 31. Hassanein T, Nussler A, Friedlander L, Van Thiel DH. Responses to interferon therapy in chronic hepatitis C are associated with an increase in plasma no. Hepatology 1994;20:A257. (Poster) 32. Faruki H, Hassanein T, Ndimbie OK, Schade R. Comparison of HBV DNA quantities by two different assays: clinical implications. Hepatology 1994;20:A298. (Poster) 33. Van Thiel DH, Friedlander L, Molloy PJ, Kania RJ, Caraceni P, DeMaria N, Hassanein T, Nadir A. Treatment of HCV-RNA positive individuals with normal or near normal ALT levels. Hepatology 1994;20:A260. 34. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Caraceni P, DeMaria N, Nadir A. How soon after the initiation of treatment of an episode of spontaneous bacterial peritonitis can an individual safely receive a liver transplant? Hepatology 1994;20:A1255. 35. Hassanein T, El-Ashmawy L, Stanson J, Schade R, Van Thiel DH, Todo S, Abu-El-Maged K, Whiteside T. Expression of IL-2, IL-IB and TNF alpha genes in the mucosa of intestinal allografts: The role of allograft rejection and CMV infection. Gastroenterology 1995;108:A1081. 36. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Kania R, Molloy P, Friedlander L, Van Hooser V, Jones S. New autoimmune disease onset under interferon alpha therapy of chronic hepatitis C. Gastroenterology 1995;108:A934. (Poster) 37. Fagiuoli S, Jazzar A, DeMaria N, Faruki H, Deal S, Hassanein T, Colantoni A, Sisson S, Tripp J, Gavlaer JS, Van Thiel DH, Cooper D, Zuhdi N. Prevalence of HCV infection after heart transplantation. Gastroenterology 1995;108:A1063. (Poster) 38. Gurakar A, Harnish MJ, Hassanein T, Van Thiel DH, Orr WC. Sleep pattern occurring in individuals with hepatitis C. Gastroenterology 1995;108:A1077. (Poster) 39. Van Thiel DH, Friedlander L, Hassanein T, Gurakar A, Wright H, Molloy PH, Kania RJ, Faruki H. Evidence that the duration of IFN Therapy should be tailored to the virologic response to treatment using more than one in vivo reservoir of infection. Gastroenterology 1995;108:A1192. (Poster) 40. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Nour B, Katz E. Liver transplantation for isolated primary biliary cirrhosis with associated autoimmune disease (the PBC-overlap syndrome): Is there a difference in prognosis? Gastroenterology 1995;108:A1192. 41. Van Thiel DH, Hassanein T, Nelson D, Cooper D, Samara S, Zuhdi N. Solid organ transplantation of HTLV-I/II seropositive individuals. Gastroenterology 1995;108:A1193. 42. Van Thiel DH, Rossaro L, Hassanein T, Van Hooser V, Gurakar . The use of ganciclovir plus GM-CSF to clear HVB-DNA prior to liver transplantation. Gastroenterology 1995;108:A1193. 43. Van Thiel DH, Molloy PJ, Kania RJ, Hassanein T, Faruki H, Friedlander L. The use of GM-CSF plus IFN to achieve biochemical and virologic resolution of chronic hepatitis C in prior IFN non-responders. Gastroenterology 1995;108:A1103. 44. Gaweco A, Van Thiel DH, Rustgi V, Hassanein T, El-Ashmawy L, Whiteside T, Hofmann WJ, Otto HF. Th1 cytokine pattern and defective IL-10 in chronic hepatitis C virus-infected livers. American Association for the Study of Liver Diseases. Hepatology 1995;22:915. (Poster) 45. Gaweco A, Rustgi V, Hassanein T, El-Ashmawy L, Whiteside T, Hofmann WJ, Van Thiel DH, Otto HF. Defective antiviral cytokines in chronic hepatitis C virus-infected livers. American Association of the Study of Liver Diseases Hepatology 1995;22:917. (Poster) 46. Bayraktar M, Bayrakatar A, Gurakar A, Hassanein T, Van Thiel DH. Comparison of the prevalence of auto-antibodies in chronic hepatitis C patients with those of auto-antibodies in autoimmune hepatitis patients. Hepatology 1995;22:1146. 47. Hassanein T, Van Thiel DH, Frank H, Gurakar A, Van Hooser V. The prevalence of chronic hepatitis at a methadone clinic. Hepatology 1995;22:A426. 48. Van Thiel DH, Hassanein T, Gurakar A, Wright HI, Faruki H, Nour B, Katz E, van Hooser V, Jones S, Kraft P, Reynolds P, Cralson J, Mason K. The use of IFN-Alpha in Liver Transplant Recipients with HCV-RNA Positivity. Gastroenterology 1995;108:A1193. 49. Hassanein T, Freeman J, Oculam CA, Albanese L, Zamora JU, Wahlstrom HE. Successful early steroid withdrawal using a tacrolimus and mycophenolate protocol for liver transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24:1579. 50. Zamora JU, Hassanein T, Oculam CA, Albanese L, Wahlstrom HE. HCV seropositivity is associated with decreased rejections and increased infections after kidney and pancreas transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24:1898. 51. Wahlstrom HE, Zamora JU, Hassanein T, Issacs B, Kirsch W. Successful use of vascular clips in liver transplantation. American Association of the Study of Liver Diseases. Hepatology 1996;24;1876. 52. Van Thiel DH, Friedlander L, Kania RJ, Molloy PJ, Hassanein T, Wahlstrom E, Faruki H. Lamivudine treatment of advanced decompensated liver disease due to hepatitis B. Gastroenterology 1997;112:A1407. 53. Mutchnick M, Tamburro C, Hassanein T, Tong M, Herrera J, Conrad A, Russell J, Blatt L. Assessment of HCV RNA and HCV Genotype from 1510 Chronic HCV Patients Treated in Community Clinical Practice in the United States Gastroenterology 1997;112:A1279. 54. Hassanein T, DeGuzman l, Bell L. High dose interferon alfa-2b is more effective in achieving viral negativity in both naïve patients and in previous non-responders with chronic hepatitis C infection. Gastroenterology 1997;112:A1254. 55. DeGuzman L, Bell L, Hassanein T. Tolerance and complications of daily high dose interferon alpha-2b. Gastroenterology 1997;112:A1254. 56. Hassanein T, DeGuzman LJ. Induction therapy with interferon alpha-2b induces rapid clearance of hepatitis C viremia in naïve patients. Hepatology 1997;26:1572. 57. De Guzman LJ, El-Mola T, Hassanein T. Induction therapy with interferon alpha- 2b induces rapid clearance of hepatitis C viremia in relapsers. Hepatology 1997;26:1473. 58. Mutchnick M, Tamburro C, Hassanein T, Tong M, Herrera J, Conrad A, Russel J, Blatt L. Analysis of HCV-RNA concentrations by a multi-cycle RT-PCR assay in 3538 untreated chronic HCV patients: Assessment of RNA titer by HCV genotype. Hepatology 1997;26:231. 59. Hassanein T, Behling C, Chatfield E, Monson P, Nguyen T. Maintenance of Interferon Therapy Inhibits Progression of Cirrhosis in Chronic Hepatitis C Infection. AJG 1998;93:A447. 60. Hassanein T, Monson P, Chatfield E, DeGuzman L, El-Mola T. High ANA Levels Do Not Preclude Interferon Therapy in Patients with Chronic Hepatitis C Infection. AJG 1998;93:A269. 61. Hassanein T, Monson P, DeGuzman LJ, Nguyen TY, Lyche KD, Chatfield ER, Hanson K, Rond RL, El-Mola TM, Hardison WG. In HCV Relapsers: Induction Course of Interferon Alfa 2B Improved the Response to Combination Therapy. Hepatology 1998;28:578A. 62. Hassanein T, Monson P, Nguyen TY, DeGuzman LJ, Lyche KD, Chatfield ER, Hanson K, Rond RL, El-Mola TM, Hardison WG. In HCV Non-Responders: Combination Therapy is More Effective Than Induction Therapy in Achieving Viral Clearance. Hepatology 1998;28:571A. 63. Hassanein T, DeGuzman, LJ, Monson P, El-Mola TM, Hanson K, Chatfield ER, Hart ME. Prolonged HCV-Suppression Using Daily Interferon Alfa Increases the Sustained Response in Naïve Patients. Hepatology 1998;28:713A. 64. Hassanein T, Martin R, Mehta R, Ward D, Hart M. Neurologic Improvement in Deeply Comatose patients in Acute On Chronic Liver Failure Treated with Extracorporeal Blood Detoxification. Hepatology 1998;28:750A. 65. Hassanein T, Hart ME, Monson P, Chatfield ER, Hwang S. Lamivudine Improves the Cholestatic Phase of Acute Hepatitis B Infection. Hepatology 1998;28:727A. 66. Huang SM, DeGuzman LJ, Chan DC, Hassanein TI, Lawson T. Iron Saturation Levels May Predict Response to Induction Dose Interferon Therapy in Patients with Chronic Hepatitis C Infection. Hepatology 1998;28:A1660. 67. DeGuzman LJ, Chan DC, Huang SM, Hassanein TI, Hanson K, Leckernby DL. Induction Therapy with Interferon Alpha-2B Increases Clearance of Hepatitis C Viremia in Naïve Patients. Hepatology 1998;28:A2440. 68. Hassanein T, Monson P, Behling C, Chatfield E, Taha H, Mohanty S, Aronson N, Medley K, Hardison WG. In HCV Naïve Patients: Combination Therapy Improves Viral Clearance When Compared to Induction Therapy. Gastroenterology 1999;116:L0172. 69. Hassanein T, Behling C, Monson P, Chatfield E, Taha H, Mohanty S, Aronson N, Hardison WG. Histology of Chronic HCV Based on Genotype. Gastroenterology 1999;116:L0173. 70. Hassanein T, Behling C, Monson P, Chatfield E, Taha H, Mohanty S, Aronson N, Hardison WG. Fibrosis Score and Platelet Level in Patients with Chronic HCV. Gastroenterology 1999;116:L0174. 71. Rose S, Pretorius D, Nelson T, Kinney T, Huynh T, Roberts A, Valji K, D'Agostino H, James G, Orloff M, Hassanein T, Hart M. Adjunctive 3D US Guidance for Achieving Portal Vein Access During Tips Procedure: The Influence of Directional Cues and Procedural Education. Radiology 1998;209:A1097. 72. Koehler G, Hart M, Hassanein T, Martin R, Mehta R. The Presence of Renal Insufficiency Influences Outcome from Liver Transplantation. J Am Soc Nephrol 1999;10:A146. 73. Mello M, Kono Y, Ferret C, Hassanein T, Hart M, Mattrey R. Contribution of Feridex to Liver MRI in End Stage Liver Disease. Radiology 1999;213:A311. 74. Mattrey R, Kono Y, Mello M, Hassanein T, Hart M. Contribution of Feridex to Liver MRI in End Stage Liver Disease. Hepatology 1999;30:A469. 75. Kono Y, Mattrey R, Sirlin C, Rose S, Hassanein T. Usefulness of Gray-scale Ultrasound Contrast Enhancement for Evaluation of TIPS Stenosis. Hepatology 1999;30:A1705. 76. Kono Y, Mattrey R, Rose S, Hassanein T, Hart M. Ultrasound Contrast Gray-scale Enhancement to Detect Residual Liver Tumor or Recurrence After Ablation or Chemoembolization. Hepatology 1999;30:A2086. 77. Chen P, Mohanty S, Hwang S, Chatfield, E, Monson P, Aronson N, Hassanein T. Lamivudine Treatment in Cholestatic Acute Hepatitis B. AJG 1999;94:A310. 78. Mohanty S, Chen P, Aronson N, Monson P, Hwang S, Behling C, Masliah E, Hassanein T. Spectrum of Liver Diseases in HIV Infected Patients: A Review of Autopsy Reports. Hepatology 1999;30:A526. 79. Aronson N, Monson P, El-Mokadem H, Mohanty S, Chen P, Chatfield E, Hwang S, Rosenberg J, Lam V, Behling C, Hassanein T. Outcome and Histological Findings of Liver Biopsies in a Cohort of HIV Infected Patients. Hepatology 1999;30:A519. 80. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Medley K, Do D, Ma M, Hwang S, Hardison WG. In HCV Non-Responders: Combination Therapy is More Effective Than Induction Therapy in Achieving Viral Clearance. Hepatology 1999;30:A1864. 81. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Medley K, Hwang S, Do D, Ma M, Hardison WG. In HCV Relapsers: Induction Therapy Does Not Improve Viral Clearance Compared to Combination Therapy. Hepatology 1999;30:A154. 82. Hassanein T, Monson P, Behling C, Chatfield E, Aronson N, Chen P, Hwang S, Hardison WG. Combination Therapy Results in a Significant Reduction in Transaminase Levels in Patients with Normal Pre-Treatment Transaminase Levels. Hepatology 1999;30:A177. 83. Monson P, Behling C, Chen P, Mohanty S, Chatfield E, Aronson N, Oliver D, Hassanein T. Virologic and Biochemical Response to Treatment in Patients with Chronic Hepatitis C with Elevated Gamma Glutamyl Transpeptidase. Hepatology 1999;30:A1804. 84. Behling C, Monson P, Chen P, Chatfield E, Aronson N, Oliver D, Hassanein T. Bile Duct Injury in Patients with Chronic Hepatitis C and Normal or Elevated Gamma Glutamyl Transpeptidase Levels. Hepatology 1999;30:A1803. 85. Martin R, Chatfield E, Albanese L, Hwang S, Hart M, Hassanein T. The evolving Role of Nursing in Liver Disease Management: Creation of a Liver Management Team. Hepatology 1999;30:A2114. 86. Hassanein T, Aronson N, Behling C, Torriani F, Chatfield E, Chen P, Mathews C. Disease Severity of HCV Infection in HIV/HCV Coinfected Patients. Gastroenterology 2000;18:A197. 87. Hassanein T, Aronson N, Behling C, Torriani F, Chatfield E, Chen P, Mathews C. The Role of HAART on HCV Disease Severity in HIV/HCV Coinfection. Gastroenterology 2000;118:A6558. 88. Chen P, Monson P, Behling C, Lam V, Hassanein T. Histological and Virological Features of HCV Patients With and Without History of Jaundice. Gastroenterology 2000;118:A6495. 89. Chen P, Monson P, Chatfield E, Pozza R, Krinsky M, Hassanein T. In HCV Naïve Patients: Combination Therapy with Daily Interferon Improves Viral Clearance When Compared to Induction Therapy. Gastroenterology 2000;118:A6493. 90. Chen P, Monson P, Behling C, Chatfield E, Pozza R, Krinsky M, Hassanein T. Combination Therapy with or without Induction for Non-Responders to Interferon Monotherapy. Gastroenterology 2000;18:A6492. 91. Behling C, Monson P, Pohl A, Aronson N, Chen P, Oliver D, Hassanein T. Bile Duct Injury, Elevated GGT and Response to Treatment in Non-Cirrhotic Hepatitis C. Gastroenterology 2000;118:A6469. 92. Hilsabeck R, Hassanein T, Perry W. Life and Illness Satisfaction for Patients with Chronic Hepatitis C. Gastroenterology 2000;118:A6564. 93. Hilsabeck R, Hassanein T, Perry W. Severity of Depression and Anxiety in Patients with Chronic Hepatitis C. Gastroenterology 2000;118:A6563. 94. Hilsabeck R, Hassanein T, Perry W. Impaired Quality of Life Varies Among Subsamples of Patients with Chronic Hepatitis C. Gastroenterology 2000;118:A6562. 95. Pohl A, Behling C, Oliver D, Kilani M, Monson P, Hassanein T. Liver Transaminase Levels and Platelet Counts as Predictors of Degree of Fibrosis in Chronic Hepatitis C. Gastroenterology 2000;118:A261. 96. Mathews C, Aronson N, Hassanein T. Prevalence of HCV in an HIV cohort at a University HIV Clinic. Gastroenterology 2000;118:A211. 97. Chen P, Behling C, Monson P, Aronson N, Chatfield E, Hassanein T. Response and Tolerance to Prolonged Induction Interferon -2a in Naïve Chronic Hepatitis C. Gastroenterology 2000;118:A6494. 98. Di Bisceglie AM, Schwartz M, Reddy R, Martin P, Gores G, Lok A, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Blei A. Hepatitis C and Hepatocellular Carcinoma in African Americans. Gastroenterology 2000;118:A6514. 99. KonoY, Mattrey RF, Pinnell SP, McKlendin K, Rose S, Hassanein T. Ultrasound Angiography with intravenous contrast agent using wideband gray-scale harmonic imaging for evaluation of TIPS stenosis. Gastroenterology 2000;118:A990. 100. Kono Y, Mattrey RF, Pinnell SP, Rose S, Hassanein T, Hart M. Characterization of the Liver Tumors and Evaluation of the Treatment of HCCS with Ultrasound Contrast Enhancement Using Wideband Gray-Scale Harmonic Imaging. Gastroenterology 2000;118:A1067. 101. Hilsabeck R, Perry W, Hassanein T. Severity and Co-Morbidity of Depression and Anxiety in Patients with Chronic Hepatitis C not Receiving Antiviral Therapy. AJG 2000;95:2513-A348. 102. Hilsabeck R, Perry W, Hassanein T. Life and Illness Satisfaction for Patients with Chronic Hepatitis C. AJG 2000;95:2512-A346. 103. Hilsabeck R, Perry W, Hassanein T. Mood Impairment in HCV Patients with and without a History of Intravenous Drug Use. AJG 2000;95:2512-A347. 104. Monson P, Oliver D, Pohl A, Behling C, Aronson N, Rossetti L, Hassanein T. Factors Associated with Steatosis in Patients with Chronic Hepatitis C. AJG 2000;95:2517-A361. 105. Hassanein T, Monson P, Behling C, Krinsky M. Combination Therapy Results in a Significant Reduction in Transaminase Levels in Patients with Pre-Treatment Transaminase Levels. AJG 2000;95:2512-A345. 106. Hilsabeck R, Perry W, Hassanein T. Attention and Memory Functioning in Non-Cirrhotic Patients with Chronic Liver Disease. Hepatology 2000;32:A1650. 107. Hilsabeck R, Hickman S, Boland B, Oliver D, Hart M, Perry W, Hassanein T. Cognitive Dysfunction in Patients with and without a History of Hepatic Encephalopathy. Hepatology 2000; 32:A1476. 108. Hilsabeck R, Perry W, Hassanein T. Measures of Fatigue in Patients with Chronic Hepatitis C. Hepatology 2000;32:A1565. 109. Hilsabeck R, Hickman S, Boland B, Oliver D, Hart M, Khanna A, Perry W, Hassanein T. Degree of Cognitive Impairment in Patients Evaluated for Liver Transplant. Hepatology; 32: A1786. 110. Kono Y, Mattrey R, Pinnell S, Rose S, Hart M, Hassanein T. Assessment of HCC Viability After Therapy in Cirrhotic Patients with Contrast-Enhanced Wideband Grayscale Harmonic Imaging. Hepatology 2000;32:A277. 111. Albanese L, Medley K, Pozza R, Peeters R, Wahlstrom E, Hassanein T. Prevalence of Hepatitis C in Community Based Screening Programs in Southern California. Hepatology 2000;32:A1566. 112. Hassanein T, Oliver D, Monson P, Pohl A, Aronson N, Rossetti L, Krinsky M, Hart M. Comparison of High Dose Interferon Plus Low Dose Ribavirin to Low Dose Interferon Plus Standard Dose Ribavirin. Hepatology 2000;32:A1647. 113. Oliver D, Monson P, Pohl A, Campbell D, Hassanein T. Interferon, Body Mass Index and Response to Treatment in Chronic Hepatitis C. Hepatology 2000;32:A1646. 114. Rose S, Kinney T, Stella D, Hart M, Hassanein T, Pretorius D, Nelson T, Levin D, Khanna A. Three-dimensional ultrasound (3D US) for estimation of left lateral segment liver volume for split liver donation. Pediatric Transplantation 2000;4:P66. 115. Rose S, Roberts A, Kinney T, Valji K, Hassanein T, Lavine J, Hart M, Khanna A. Integral role of interventional radiology in the development of a pediatric liver transplantation program. Pediatric Transplantation 2000;4:P322. 116. Khanna A, Lavine J, Cashman J, Garfinkel M, Hall K, Frankville D, Randle C, Nyhan W, Wahlstrom E, Hassanein T, Hart M. First year evaluation of new pediatric abdominal transplantation program at a major teaching hospital. Pediatric Transplantation 2000;4:P86. 117. Khanna A, Gutmacher H, Garfinkel M, Cashman J, Hall K, Randall C, Greenburg M, Frankville D, Dohil R, Shapiro W, Taylor S, Wahlstrom E, Hassanein T, Nyhan W, Lavine J, Hart M. Early enteral feeding obviates the need for parenteral nutrition in pediatric liver transplant (OLTX) patients. Pediatric Transplantation 2000;4:P93. 118. Khanna A, Lavine J, Hassanein T, Hart M. Setting up pediatric abdominal transplantation program in a managed care environment: preliminary experiences. Pediatric Transplantation 2000;4:P294. 119. Hilsabeck R, Hassanein T, Perry W. Prevalence of Impaired Cognitive Functioning in Outpatients with Chronic Liver Disease. Archives of Clinical Neuropsychology 2000;15:705. 120. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T. Usefulness of Gray-scale Ultrasound Contrast Enhancement for Evaluation of TIPS Stenosis. Journal of Ultrasound in Medicine 2000;19:P65 121. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T, Hart M. Evaluation of Tumor Vascularity-Characterization and Evaluation of the Treatment. Journal of Ultrasound in Medicine 2000;19:P23. 122. Wasserman R, Brau N, Hassanein T, Bini E, Sulkowski M, Dieterich D. Once Weekly Epoetin Alfa Increases Hemoglobin and Decreases RBV Discontinuation Among HCV Patients Who Develop Anemia on RBV/INF Therapy. Hepatology 2000;32:A833. 123. Khanna A, Lavine J, Hassanein T, Garfinkel M, Hall K, Frankville D, Wahlstrom E, Hart M. First Year Evaluation of Living Related Liver Transplantation Program at a Major Teaching Hospital. First Congress International Pediatric Transplantation Association, Rome Italy, August 2000. 124. Hart M, Hassanein T, Rose S, Roberts A, Kenny T, Garfinkel M, Wahlstrom E, Lavine J, Khanna A. Evaluation and Outcome of Living Related Donors for Liver Transplantation. Workshop on Living Donor Liver Transplantation, NIH, December 2000. 125. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T. Ultrasound Contrast Venography of TIPS – Gray-scale Ultrasound vs X-ray Venography. AIUM 2001. 126. Kono Y, Mattrey R, Pinnell S, Rose S, Hassanein T, Hart M. Contrast-Enhanced B-mode Harmonic Imaging for the Evaluation of HCC Viability after Therapy in Cirrhotic Patients. AIUM 2001. 127. Oliver D, Hilsabeck R, Rossetti L, Aronson N, Behling C, Hassanein T.Platelet Count as a Predictor of Fibrosis Stage in HIV/HCV Co-Infected Patients. Gastroenterology 2001;120:A-515. 128. Oliver D, Hilsabeck R, Rossetti L, Barber E, Mathews WC, Hassanein T. The Impact of HCV on Survival of HIV-Infected Patients. Gastroenterology 2001;120:A-516. 129. Hilsabeck R, Carlson M, Hassanein T, Perry W. Relationship of Depression and Anxiety Symptoms to Disease Severity in Patients with Chronic Hepatitis C. Annals of Behavioral Medicine2001: 23,S038. 130. Hilsabeck R, Carlson M, Hassanein T, Perry W. Social Support of Patients with Chronic Hepatitis C. Annals of Behavioral Medicine 2001;23:S186. 131. Hilsabeck, RC, Carlson, MD, Perry, W, Hassanein, TI. Comparison of Emotional and Cognitive Functioning in Patients Pre- and Post- Liver Transplant, American Journal of Transplantation 2001;1:422. 132. Hilsabeck R, Hickman S, Boland B, Williams B, Boyd C, Hassanein T, Perry W. The pattern of memory deficits in patients with end stage liver disease. Journal of the International Neuropsychological Society 2001;7:169. 133. Hilsabeck R, Hassanein T, Perry W. Attention and Memory Impairment in Noncirrhotic Patients with Liver Disease. Journal of the International Neuropsychological Society 2001;7:169. 134. Hilsabeck R, Hickman S, Boland B, Williams B, Boyd C, Hassanein T, Perry W. Neuropsychological Functioning of Patients Evaluated for Liver Transplantation. Journal of the International Neuropsychological Society 2001;7:169. 135. Rose S, Hassanein, T, Easter D, Gamagami R, Bouvet M, Pretorius D, Nelson T, Kinney T, James G. Value of Three-dimensional US for Optimizing Guidance for Ablating Focal Liver Tumors, JVIR 2001, 12:507. 136. Dieterich DT, Wasserman R, Brau N, Hassanein TI, Bini EJ, Sulkowski M. Once-weekly Recombinant Human Erytopoetin (Epoetin Alfa) Facilitates Optimal Ribavirin (RBV) Dosing in Hepatitis C virus (HCV)-infected Patients Receiving Interferon--2b (IFN)/RBV Combination Therapy, Gastroenterology 2001;120:A-64. 137. Stange J, Mitzner S, Hassanein TI, Mehta R, Bartlett R, Albumin Dialysis as a New Tool for Extracorporeal Liver Support-Clinical Data from 19 Centers Reporting 103 Patients and Two Prospective Randomized Controlled Trials, Gastroenterology 2001;120:A-542. 138. Thomas JL, Hilsabeck RC, Carlson MD, Hassanein, TI, Perry W. Validation of the Index of Readiness Scale in Patients with Chronic Hepatitis C, Annals of Behavioral Medicine 2001;23:187(supp). 139. Hilsabeck R, Ziegler B, Carlson M, Rossetti L, Stewart M, Perry W, Hassanein T. Course of Depression, Anxiety, and Fatigue in HCV Patients on and Off Antiviral Therapy. ACG Scientific Meeting 2001:P114. (Poster) 140. Hilsabeck R, Carlson M, Ziegler B, Medley K, Aronson N, Chatfield E, Perry W, Hassanein T. Relationship of Chronic HCV Infection, Intravenous Drug Use and Psychiatric History to Depression and Anxiety. ACG Scientific Meeting 2001:P113. (Poster) 141. Hassanein T, Abdeen Om Martin R, Khanna A, Hart M, Mehta R. Octreotide and Albumin Infusion in the Treatment of Decompensated End Stage Liver Disease and Oliguria. ACG Scientific Meeting 2001: P622. (Oral) 142. Stange J, Hassanein T. Albumin Dialysis Using the MARS as a Treatment of End Stage Liver Disease and Progressive Cholestasis. ACG Scientific Meeting 2001:P623. (Oral) 143. Khanna A, Hall K, Perry W, Selim K, Hassanein T, Hart M. An Analysis of Causes of Donor Withdrawal in Adult to Adult Living Related Liver Transplant Program. AASLD 2001. (Poster) 144. Hilsabeck RC, Carlson MD, Ziegler BA, Hassanein TI, Perry W. The Relationship of Fatigue and Cognitive Functioning in Patients with Chronic Hepatitis C. Archives of Clinical Neuropsychology 2001;16:728. 145. Ziegler BA, Hilsabeck RC, Carlson MD, Hassanein TI, Perry W. Resolution of Cognitive Impairment after Liver Transplantation: A case study. Archives of Clinical Neuropsychology 2001;16:738. 146. Hassanein T, Aronson N, Oliver D, Barber E, Hilsabeck R, Chatfield E, Stewart M, Mathews C. Survival in HCV/HIV Co-Infected Patients. Hepatology 2001;34:232A. 147. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai MY, Pastore G, Trejo-Estrada R, Vale A, Lok A, Lin A. Treatment With 40 KDA Peginterferon Alfa-2A (PEGASYS) in Combination with Ribavirin Significantly Enhances Quality of Life Compared with Interferon Alfa-2B Plus Ribavirin. Hepatology 2001;34:243A. 148. Khalili M, Hoffman-Terry M, Hassanein T, Bernstein D, Harb G, Pearson D. Safety and Efficacy of 40 KDA Peginterferon Alfa-2A (PEGASYS) in the Treatment of Patients Co-Infected with HIV and HCV: Preliminary Results from a Randomized Multi-Center Trial. Hepatology 2001;34:328A. 149. Hassanein T, Mehlman L, Barber E, Hall K, El-Tahawy M, Mathews C. Survival of Patients with Acute Cholestasis. Hepatology 2001;34:524A. 150. Hassanein T, Abdeen O, El-Tahawy M, Hart M, Khanna A, Mehta R. Octreotide, Midodrine and Albumin, Triple Therapy is Effective in Reversing Hepatorenal Syndrome. Hepatology 2001;34:542A. 151. Oliver D, Aronson N, Chargield E, Stewart M, Hilsabeck R, Mathews C, Hassanein T. Effectiveness of Interferon/Ribavirin Combination Therapy in HIV/HCV Co-Infected Patients. Hepatology 2001;34:584A. 152. Hassanein T, Lyche K, Balan V, Winston D, Rossi S, Rossetti L, Crayne K, Oliver D, Hilsabeck R. Efficacy of Peg-Intron and Ribavirin in HCV Non-Responders. Hepatology 2001;34:585A. 153. Hassanein T, Hilsabeck R, Carlson M, Hwang S, Medley K, Ziegler B. Assessment of Quality of Life in Sustained Responders. Hepatology 2001;34:600A. 154. Hilsabeck R, Carlson M, Cheung G, Ziegler B, Oliver D, Mathews C, Perry W, Hassanein T. Comparison of Psychiatric Symptoms in Patients with Hepatitis C, Human Immunodeficiency Virus and Co-Infection. Hepatology 2001;34:602A. 155. Hassanein T, Barber E, Mehlman L, Hwang S, Costanza C, Mathews C. Comparative Analysis of Meld Versus Discriminate Function as a Predictor of Patient Mortality in Alcoholic Hepatitis. Hepatology 2001;34:457A. 156. Stange J, Broelsch C, Gerken G, Treichel U, Heemann U, Liebe S, Hassanein T. Predictably LTX-Costs of Progressive Cholestasis in End Stage Liver Disease can be Reduced by Albumin Dialysis Results of a Prospective Controlled Randomized Trial. Hepatology 2001;34:650A. 157. Hagey L, Stange J, Hassanein T. Removal of Toxic Components of Plasma by the Molecular Absorbing Recirculating System (MARS) in Patients with Cholestatic Liver Failure. Hepatology 2001;34:661A. 158. Stange J, Hassanein T, Gerken G, Treichel U, Heemann U, Mitzner S. Hepatic Encephalopathy in End Stage Liver Disease can be Improved by Albumin Dialysis-Results of a Retrospective Analysis and a Prospective Randomized Controlled Trial. Hepatology 2001;34:661A. 159. Stange J, Hassanein T, Hwang S. Albumin Dialysis as a Bridge to Transplant in Chronic Liver Disease Complicated by Progressive Cholestasis. Hepatology 2001;34:661A. 160. Khanna A, Hall K, Perry W, Selim K, Hassanein T, Hart M. An Analysis of Causes of Donor Withdrawal in an Adult to Adult Living Related Liver Transplant Program. Joint Transplant Meeting of the American Society of Transplant Surgeons and American Society of Transplantation, April-May 2002. 161. Stange J, Hassanein T, Klammt S, Mitzner S, Lock J, Oliver D. Binding Capacity of the Albumin's Benzodiazepine Binding Site as a New Parameter for Monitoring Clinical Course of Excretory Liver Failure. DDW May 2002: ID 108436. (Poster) 162. Oliver D, Stewart M, Chatfield E, Aronson N, Selim K, Matthew C, Hassanein T. Efficacy of Interferon Alpha-2b plus Ribavirin Combination Therapy in HIV/HCV Co-infected Patients. DDW May 2002: ID102516. (Poster) 163. Metwally M, Hassanein T, Zein C, Selim K, Oliver D, Behling C, Zein N. A Simple Non-Invasive Scoring System for Prediction of Severe Hepatic Fibrosis in Chronic HCV Patients Co-Infected with HIV. DDW May 2002: ID 108422. (Poster) 164. Vaquero J, Oliver D, Hassanein T, Stange J, Blei A. Evaluation of Mental State in a Clinical Trial of M.A.R.S. for Patients with Acute Hepatic Encephalopathy: Comparison of Two Scales. Scientific Meeting May 2002. (Oral) 165. Khanna A, Lavine A, Precht T, Hassanein T, Hall K, Frankville D, Wahlstrom HE, Hart M. Living Related Pediatric Liver Transplant: Early Experiences. Abdominal Organ Transplantation from Living Donors: State of the Art Meeting, Gubbio Italy, June 2002. 166. Khanna A, Lavine J, Hassanein T, Precht A, Hart M. Setting Up Living Donor Pediatric Transplant Program. Abdominal Organ Transplantation from Living Donors: State of the Art Meeting, Gubbio Italy, June 2002. 167. Khanna A, Lavine J, Hassanein T, Hart M. Setting up Pediatric Abdominal Transplantation Program in a Managed Care Environment: Preliminary Experiences. International Liver Transplantation Society, June 2002. 168. Fried M, Shiffman M., Reddy R, Smith C, Marinos G, Gonzales G, Haussinger D., Diago M., Giampiero C., Dhumeaux D., Craxi A., Lin A., Hoffman J., Yu J., Hassanein T. Peginterferon Alfa-2a Plus Ribavirin for Chronic Hepatitis C Virus Infection. N Engl J. Med, September 2002:347:13. 169. Khanna A, Precht AF, Lavine J, Hall K, Brink JA, Hassanein T, Hart M. Living Related Pediatric Liver Transplant: Early Experiences. 2nd Congress of International Pediatric Transplant Association, Rio de Janiero, April 2003. 170. Khanna A, Hart ME, Precht AF, Brink JA, Lavine J, Hall K, Hassanein T, Nyhan W. Lateral Segment Liver Transplantation from Adult Donors: A Practical Alternative to Ameliorate metabolic Diseases in Pediatric Patients. 2nd Congress of International Pediatric Transplant Association, Rio de Janiero, April 2003. 171. Hassanein T, Oliver D, Stange J. Management of Post-Graft Dysfunction (PGD) in Cadaveric and Living-Related Liver Transplantation by Albumin Dialysis (MARS) ITLS June 2003. (Poster) 172. Stange J, Broelsch C, Gerken G, Heemann U, Hassanein T. Reduction of Predictable LTX Costs in Liver Failure by Pre-conditioning Albumin Dialysis Resulting in Maintaining Kidney Function; Investigators Lead of a Prospective Randomized Trial. ITLS June 2003. (Poster) 173. Stange J, Hassanein T. Predictably LTx-Costs of progressive cholestasis in end stage liver disease can be reduced by albumin dialysis – results of a prospective controlled randomized trial. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003 174. Hassanein T, Oliver D. Emergency use of Albumin dialysis (MARS) in cirrhotic patients with progressive hyperbilirubinemia in the US-Allocation system. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003. 175. Stange J, Hassanein T, Oliver D. Bilirubin trend predicts renal failure and death in cirrhotics with superimposed acute injury on LTX waiting list. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003 176. Hassanein T,Oliver D. Hepatic Coma in Post Graft Dysfunction can be resolved by albumin dialysis (MARS). Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003 177. Tong M, Hassanein T, Van Antwerp W, Olek E, Murphy B. Delivery of Consensus Interferon by Continuous Infusion for the Treatment of Chronic Hepatitis C: A Pilot Viral Kinetic Study in Nonresponder Patients. AASLD October 2003. (Poster) 178. Stange J, Siekmoller M, Oliver D, Chauhan DP, Hassanein T. Cytochrome P450 Isoform Dysfunction in Alcoholic Hepatitis Can Be Reversed by Albumin Dialysis (MARS). AASLD October 2003. (Poster) 179. Hassanein T, Hilsabeck R, Marcott T, Carlson M, Perry W. Driving Performance in Patients with Chronic Liver Disease. AASLD October 2003. (Poster) 180. Hassanein T, Barakat F, Myers W, Carlson M, Chatfield E, Selim K, Behling C. Effect of Peg Interferon Alpha-2B and Ribavirin Dose on the Histologic Changes in Virologic Nonresponders to the Combination of Standard Interferon Alpha-2B and Ribavirin: A Randomized Controlled Study. AASLD October 2003. (Poster) 181. Hassanein T, Hilsabeck R. Hepatitis C and Cognitive Impairment. The HCV Advocate: Medical Writer’s Circle. August 2003. 182. Hassanein T, Stange J. The molecular adsorbents recycling system as a liver support system based on albumin dialysis: A summary of preclinical investigations, prospective, randomized controlled clinical trial, and clinical experience from 19 centers. Artifical Organs, Volume 26, Issue 2. 183. Hassanen T, Oliver D, Stange J, Steiner C. Albumin dialysis in cirrhosis with superimposed acute liver injury: Possible impact of albumin dialysis on hospitalization costs. Liver International 2003: 23(suppl 3):61-65. 184. Hassanein T, Zeh N, Rossi S, Hofmann A, Steinbach J, Hagey L, Oliver D, Stange J. The effect of extracorporeal albumin dialysis on plasma phospholipid fatty acids in patients with end-stage liver disease. Liver International 2003: 23(suppl 3):34-38. 185. Hassanein T, Deiterich D, Wasserman R, Norbert B, Bini E, Bowers P, Sulkowski M. Once-weekly epoetin alfa improves anemia and facilitates maintenance of Ribavirin dosing in hepatitis C virus-infected patients receiving Ribavirin plus interferon alfa. American Journal of Gastroenterology. November 2003. 186. Hassanein T, Pillai G, Srivastava A, Chuahan D, Carrier E. Induction of apoptosis in human lung cancer cells by curcumin. Cancer Letters. 2004. 187. Hassanein T, Kinney T, Ferrara S, Miller F, Roberts A. Transjugular intrahepatic portosystemic shunt creation as treatment for refractory chylous ascites and chylothorax in patients with cirrhosis. Journal of Virology January 2004. 188. Hassanein T, Kono Y, Alton K, Rose S, Mattrey R. Early assessment of treatment success with contrast-enhanced ultrasound post-transarterial chemoembolization for Hepatocellular carcinoma. 189. Hassanein T, Cooksley G, Sulkowski M, Smith C, Marinos G, Lai M, Pastore G, Trejo-Estrada R, Vale A, Wintfield N, Green J. The impact of peginterferon alfa 2a plus Ribavirin combination therapy on health-related quality of life in chronic hepatitis C. Journal of Hepatology 40 (2004)675-681. 190. Stange J, Hassanein T. Predictably LTx-Costs of progressive cholestasis in end stage liver disease can be reduced by albumin dialysis – results of a prospective controlled randomized trial. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany June 2003. 191. Stange J, Hassanein T, Oliver D. Bilirubin trend predicts renal failure and death in cirrhotics with superimposed acute injury on LTX waiting list. Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003. 192. Hassanein T, Oliver D. Hepatic Coma in Post Graft Dysfunction can be Resolved by Albumin Dialysis (MARS). Workshop On Experimental and Clinical Liver Transplantation and Hepatology. University Essen, Wilsede Germany. June 2003. 193. Di Bisceglie AM, Lyra AC, Schwartz M, Reddy RK, Martin P, Gores G, Lok Ash, Hussain KB, Gish R, Van Thiel DH, Younossi Z, Tong M, Hassanein T, Balart L, Fleckenstein J, Flamm S, Blei A, Befeler AS, Liver Cancer Network. Hepatitis C-related hepatocellulor carcinoma in the United States: influence of ethnic status. Am J Gastorenterol 2003; Sept;98(9):2060. 194. Hassanein T, Barakat F, Myers W, Carlson M, Chatfield E, Selim K, Behling C. (2003) Effect of Peg Interferon alpha-2b and Ribavirin dose on the histological changes in virologic non-responders to the combination of standard Interferon Alpha-2b and Ribavirin: A randomized controlled study. Hepatology 38(2) Supple 1:742A. 195. Hassanein T,Barakat F, Behling C, Myers W, Carlson M, Chatfield E, Selim K (2003). Effects of the Combination of Peg-Interferon Alpha-2b and Ribavirin on the inflammation and fibrosis scores of patients with chronic Hepatitis C infection who were virologic non-responders to Interferon Alpha-2b and Ribavirin. The American Journal of Gastroenterology 98, (9), S103 196. Hassanein T,Barakat F, Behling C, Myers W, Carlson M, Chatfield E, Selim K. Effects of the combination of Peg-Interferon alpha-2b and Ribavirin on the inflammation and fibrosis scores of patients with chronic hepatitis C infection who were virologic non-responders to Interferon Alpha-2b and Ribavirin. 10/2003 68th Annual Meeting for the American College of Gastroenterology (ACG), Baltimore, MD, Poster Presentation. 197. Lynch P, Hassanein T, Hilsabeck R, Stange J, Blei A. Grading Hepatic Encephalopathy in a Controlled Trial of MARS. Performance of Two Scales. Hepatology 2004;34:508A. 198. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz D, Hassanein T. Sleep and Fatigue in Patients with Chronic Hepatitis C. Hepatology 2004;34:248A. 199. Aguirre D, Sirlin C, Alpert E, Behling C, Mattrey R, Hassanein T. Accurate Non-Invasive Diagnosis of Liver Fibrosis Using MR Imaging. Hepatology 2004;34:707A. 200. Hassanein T, Tofteng F, Brown R, McGuire B, Lynch P, Mehta R, Larsen F, Gornbein J, Stange J, Blei A. Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of hepatic Encephalopthy: A Prosective Controlled, Randomized Multicenter Trial. Hepatology 2004;40:726A 201. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz D, Hassanein T. Sleep and fatigue in patients with chronic hepatitis C. 10/2004 55thAnnual Meeting for the American Association for the Study of Liver disease (AASLD), Boston, MA. Oral Presentation. 202. Lynch P, Hassanein T, Hilsabeck R, Stange J, Blei A. Grading Hepatic Encephalopathy in a Controlled Trial of Mars: Performance of Two Scales. AASLD, November 2004. (Poster) 203. Kono Y, Alton K, Rose S, Hassanein T, Mattrey R. The Ability of Contrast-Enhanced Ultrasound (CEUS) to Predict Final Outcome within 1 week after Transarterial Chemoembolization (TACE) for Hepatocellular Carcinoma (HCC). AASLD, November 2004. (Poster) 204. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz D, Hassanein T. Sleep and Fatigue in Patients with Chronic Hepatitis C. AASLD, November 2004. 205. Hassanein T, Tofteng F, Brown R, McGuire B, Lynch P, Mehta R, Larsen F, Gornbein J, Stange J, Blei A. Efficacy of Albumin Dialysis (MARS) in Patients with Cirrhosis and Advanced Grades of Hepatic Encephalopathy: A Prospective Controlled Randomized Multicenter Trial. AASLD, November 2004. (Oral) 206. Pozza R, Biando K, Maisey A, Hassanein T. Interferon Response Rates in HCV Infected Patients Awaiting Renal Transplantation, Therapies for Viral Hepatitis, November 2004. (Oral/Poster) 207. Puckett J, Liu J, Bhalla V, Kravetz D, Krinsky M, Hassanein T, Mittal R. Ultrasound System to Measure Esophageal Varix Pressure: An In-Vitro Validation Study. Am J Physiol Gastrointest Liver Physiol. 2004 Dec 10.1152. 208. Carlson M, Barakat F, Richards L, Verbeck M, Edwards K, Quach D, Alpert E, Kravetz D, Hassanein T. (2004). Sleep and fatigue in patients with chronic hepatitis C. Hepatology 40 (4) Suppl 1:248A. 209. Zarski J, Smith C, Fried M, Hadziyannis S, Rakela J, Hassanein T, Lee S, Wright T. Are there differences in baseline characteristics or treatment outcomes with Peginterferon alfa-2a (40KD) and Ribavirin in patients infected with HCV Gentotype 1a or 1b? European Association for the Study of Liver Diseases (EASL), April 2005. 210. Fredrick RT, Hassanein TI. Role of Growth Factors in the Treatment of Patients with HIV/HCV Coinfection and Patients with Recurrent Hepatitis C Following Liver Transplantation. J Clin Gastroenterol. 2005 Jan:39(1). 211. Stange J, Steiner C, Steffen R, Mitzner R, Oliver DL, Hassanein TI, MARS Registry Group. Bridging To Liver Transplant with Albumin Dialysis-Annual Report of the International MARS Registry 2004. Am J Gastorenterol 2005; May(5):202. 212. Mokadem H, Salotti J, Richards L, Barakat E, Rose S, Behling C, Sirlin C, Alpert E, Mattrey R, Khanna A, Hart M, Hassanein T. Effect of Transarterial Chemoembolization (TACE) on Hepatocellular Carcinoma (HCC) Recurrence after Liver Transplantation: A Single Center Experience. Gastroenterology 2005;128(4 Suppl): A757. 213. Ilyas J, Oliver D, Barber E, Verbeck M, Richards L, Carlson M, Barakat F, Hassanein T. Factors that influence treatment of HIV/HCV co-infected patients. 5/2005 Digestive Disease Week (DDW). Poster Presentation. 214. Yen TY, Khanna A, Valji K, Hart M, Hassanein T. Posthepatic Portal Hypertension After a Domino Liver Transplantation Due to Pseudo-Budd Chiari Syndrome. Am J Gastorenterol. September 2005, Volume 100(9), pp S196, Abstract #517. 215. Barakat F, Carlson M, Oliver D, Barber E, Travasso J, Verbeck M, Richards L, Alpert E, Perry W, Hassanein T Pegylated Interferon and Ribavirin Combination Therapy in Patients with Psychiatric Illnesses. Hepatology 2005; 42(4 Suppl 1): 677A. 216. Shahatto L, Pozza R, Hefner A, Biando K, El-Kabany M, Hassanein T. Can HIV-HCV Coinfection be Effectively Treated in Community Based Clinics? 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation / Press Release. 217. Kased N, Kwan S, Aguirre D, Santosa A, Wolfson T, Gamst A, Hanna F, Hassanein T,Sirlin C. Improved Diagnostic and Staging Accuracy for Hepatocellular Carcinoma in Cirrhotic Patients by Combing Superparamagnetic Iron Oxide-enhanced and Multi-phasic Gadolinimum-enhanced Magnetic Resonance Imaging. 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation. 218. Kono Y, Sirlin C, Santillan C, Hughes F, Wolfson T, Alpert E, Mattrey R, Hassanein T. Non-invasive Assessment of Reticuloendothelial Function using Spio Enhanced MR allows Differentiation of Malignant versus Benign Focal Hypervascular Lesions in End Stage Liver Disease. 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation. 219. Barakat F, Carlson M, Oliver D, Edwards K, Karlen N, Hilsabeck R, Perry W, Hassanein T. Fatigue in Patients with Hepatitis C and Non-viral Chronic Liver Disease. Hepatology 2006; 44(4 Suppl 1): 319A. 220. Hassanein T, Oliver D, Carlson M, Barakat F, Mooney S, Stange J. Restoration of Neurocognitive Functions in Patients Recovering from Severe Grades of Hepatic Encephalopathy Managed by Extracorporeal Albumin Dialysis and/or Standard Medical Therapy in a Randomized Controlled Trial. Hepatology 2006; 44(4 Suppl 1): 363A. 221. Mooney S, Oliver D, Barakat F, Carlson M, Hilsabeck R, Perry W, Hassanein T. Anxiety and Depressive Symptoms in Patients with Resolving Hepatic Encephalopathy. Hepatology 2006; 44 (4 Suppl 1): 468A. 222. Bacon B, Regev A, Ghalib R, Morelli G, Rothstein K, Hassanein T, Shiffman M, Murphy B. Use of Daily Interferon Alfacon-1 (Infergen-CIFN) plus Ribavirin (RBV) in Patients Infected with Hepatitis C (HCV) who are Nonrespnders to Previous Pegylated Interferon Plus RBV Therapy: 24-week Data from the Direct Trial. 57thAnnual Meeting of the American Association for the Study of Liver Disease (AASLD), October 2006. Poster Presentation. 223. Mooney S, Barakat F, Carlson M, Oliver D, Hilsabeck R, Perry W, Alpert E, Hassanein T. Comparison of Two Assessment Methods for Grading Hepatic Encephalopathy. Gastroenterology 2006; 130(4 Suppl): A809. 224. Amer MO, Richards LM, Barakat F, Kono Y, Rose S, Hart M, Alpert E, Hassanein T. Impact of Transarterial Chemoembolization on the Outcome of Hepatocellular Carcinoma. Gastroenterology 2007; 132(2 Suppl): A202. 225. Amer M, Youssri M, Barakat F, Naga Y, Kono Y, Richards LM, Alpert E, Sirlin CB, Rose S, Hart M, Khanna A, Hassanein T. Pretransplant Chemoembolization for Hepatocellular Carcinoma <= 3 cm Dose Not Influence the Outcome after Liver Transplantation. Hepatology 2007; 46(4 Suppl 1): 618A. 226. Bacon B, Regev A, Ghalib R, Morelli G, Rothstein K, Shiffman M, Hassanein T, Hammond J. The Direct Trial (Daily-Dose Consensus Interferon and Ribavirin: Efficacy of Combined Therapy): Treatment of Non-Responders to Previous Pegylated Interferon plus Ribavirin Sustained Virologic Response Data. Hepatology 2007; 46(4 Suppl 1): 311A. 227. Oliver D, Barakat F, Carlson M, Perry W, Stange J, Hassanein T. Patients with Severe Hepatic Encephalopathy have Different Patterns of Recovery of Neurocognitive Dysfunctions. Hepatology 2007 46(4 Suppl 1): 860A. 228. Hassanein T, Ghalib R, Zein N, Rothstein K, Joshi S, Kwo P, Hammond J. Analysis of Relapse Rates in Pegylated Interferon and Ribavirin Non-Responders Treated with Daily Concensus Interferon and Ribavirin. Hepatology 2007; 46(4 Suppl 1): 824A. 229. “Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin”, European Association for the Study of Liver Diseases (EASL), Milan Italy, April 2008. (Poster Presentation). 230. “Clinical and Persistency Outcomes in Hepatitis C Patients Treated with Peginterferon alfa-2a or Peginterferon alfa-2b plus Ribavirin”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation). 231. “Factors Contributing to the Low Rate of HCV Evaluation in HIV/HCV Co-infected Cohort”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation). 232. “Difference in Presentation in Hepatocellular Carcinoma in Egyptian and US Cohorts”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Poster Presentation). 233. “Extent of Recovery of Neurocognitive Dysfunction in Patients Presenting with Severe Hepatic Encephalopathy”, Digestive Disease Week (DDW), San Diego CA, May 2008. (Oral Presentation). 234. Rose SC, Kono, Y, Sirlin C, Alpert E, Hassanein TI. Comparison of CT angiography and digital subtraction angiography for displaying vascular anatomy relevant to planning regional therapy for liver cancers. J Intervent Radio 2008;1:19-27. 07/2008